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CHAPTER 1
Introduction

Atherosclerosis is a chronic, progressive, systematic condition with a long asymptomatic 
phase. Atherosclerosis develops gradually as a subclinical condition over the life course 
and eventually becomes clinically apparent as ischemic heart disease, cerebrovascular 
disease, or peripheral arterial disease.
Subclinical atherosclerosis, or preclinical atherosclerosis, refers to the early stage of 
the atherosclerosis process when within the vascular walls “something has started to 
change”, yet the cardiovascular disease is not clinically evident. Detecting the forth-
coming disease at this stage, before the clinical manifestations, has gained interest over 
the past decade. Coronary artery calcifi cation, carotid intima-media thickness, and an-
kle-brachial index are three measures of subclinical atherosclerosis burden that can be 
detected and quantifi ed non-invasively. 
GENETICS OF SUBCLINICAL MEASURES OF ATHEROSCLEROSIS
Exploring the genetic loci associated with subclinical atherosclerosis burden in differ-
ent vascular beds provides new insights into the biological processes involved in ath-
erosclerosis initiation, progression, and complications and may ultimately suggest new 
strategies for prediction, prevention, and treatment of cardiovascular disease. Prior to 
the introduction of genome-wide association studies, the candidate gene or linkage 
studies were not successfully consistent in identifying novel genetic variants related 
to these subclinical measures of atherosclerosis; coronary artery calcifi cation, carotid 
intima-media thickness, and ankle-brachial index. However, familial aggregation and 
heritability estimates suggested a signifi cant genetic component for these measures of 
subclinical atherosclerosis burden 1-3. The advent of genome-wide association studies 
has allowed for considerable progress in identifi cation of common genetic variants 
underlying common complex disorders. Likewise, application of this approach to the 
subclinical measures of atherosclerosis reveals novel gene discoveries which open new 
windows into understanding the complex nature of the atherosclerosis process. 
• 13 •
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SUBCLINICAL MEASURES OF ATHEROSCLEROSIS AND 
CARDIOVASCULAR RISK PREDICTION
One of the most common features of atherosclerotic disease is its clinical manifestation 
as unheralded cardiovascular events. Approximately 40% to 60% of major occlusive 
atherosclerotic cardiovascular events (myocardial infarction, sudden death) occur as 
the fi rst manifestation 4. Accurate identifi cation of individuals at risk of such events is 
therefore highly desirable. This recognition formed the basis for development of differ-
ent cardiovascular risk scoring algorithms 5-7. The principle underlying all of the risk 
prediction tools is to estimate the risk of developing cardiovascular disease within a 
certain time frame, usually a 10-year window, for each individual. Assessment of the 
apparently healthy individuals for developing cardiovascular event provides the founda-
tion for targeted preventive efforts. 
The utility of the existing risk scoring algorithms, based on the traditional risk fac-
tors, to predict cardiovascular events is limited 8. Over the past few years, substantial 
effort has been devoted to examining the addition of newer risk markers to established 
risk scoring systems. Detection of subclinical atherosclerosis by non-invasive measures; 
coronary artery calcium score, carotid intima-media thickness, carotid plaque burden, 
and ankle-brachial index, has shown to be predictive of future cardiovascular events. 
Similarly, a large number of emerging risk markers are continuously developed and pro-
posed as representative measures of atherosclerosis burden 9. All of these markers, pro-
posed as indicators of cardiovascular disease risk, are frequently evaluated as potential 
additions to standard risk assessment strategies. Due to the increasing number of such 
efforts, recent guidelines recommend that several measures be used for assessing the 
increment in risk prediction accuracy offered by newer risk markers 10,11. However, data 
on direct comparisons of the subclinical measures of atherosclerosis and other newer 
risk markers in cardiovascular risk prediction within the same cohort of individuals, 
implementing the new recommendations, is limited. Use of only some of the recom-
mended assessment methods may provide misleading impressions of the clinical utility 
of novel markers in cardiovascular risk prediction.
Most of the risk scoring algorithms have traditionally focused on one specifi c compo-
nent of cardiovascular disease, generally on coronary heart disease. Recently, there has 
been an increasing recognition that the focus of risk assessment tools should be directed 
towards a broader defi nition of cardiovascular disease instead of targeting coronary 
heart disease only 12. However, when addressing the utility of newer risk markers in 
prediction of the broader cardiovascular outcome, it should be acknowledged that the 
added value of the risk marker is an aggregation of its different contributions to various 
cardiovascular components. This concept has not yet been addressed in large popula-
tion-based settings. 
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CARDIOVASCULAR DISEASE RISK PREDICTION IN WOMEN
Appreciation of the infl uence of gender on cardiovascular risk assessment and man-
agement is increasingly gaining attention. New modifi cations to the general approach 
for cardiovascular risk prediction and stratifi cation in women have recently been pro-
posed 13. It is now suggested to focus the women’s guidelines on the risk estimation 
for the broad cardiovascular outcome rather than solely for coronary heart disease. 
Moreover, lowering the threshold for defi ning the “high cardiovascular risk category” 
in women is recommended 13. Based on the observations regarding the high “lifetime” 
risk for cardiovascular disease in women 14, complementing cardiovascular risk predic-
tion in women with risk estimations for a longer term horizon is advocated 13. However, 
data on application of the new recommendations for cardiovascular risk prediction in 
women to the population-based settings is sparse. 
OUTLINE OF THIS THESIS
This thesis focuses on coronary artery calcifi cation, carotid intima-media thickness, and 
ankle-brachial index as three measures of subclinical atherosclerosis burden. 
 In the second chapter of this thesis, the aim is to unravel the genetic determinants 
of these three subclinical measures of atherosclerosis; coronary artery calcifi cation 
(chapter 2.1), carotid intima-media thickness (chapter 2.2), and ankle-brachial index 
(chapter 2.3). To investigate the association of DNA variants with these three subclinical 
measures of atherosclerosis, we use the powerful approach of genome-wide association 
(GWA) studies. The GWA studies are performed within the framework of the Cohorts for 
Heart and Aging Research in Genetic Epidemiology (CHARGE) Consortium 15. 
The third chapter of this thesis focuses on the predictive ability of subclinical measures 
of atherosclerosis in cardiovascular disease risk prediction. In chapter 3.1, the predic-
tive performance of carotid intima-media thickness in prediction of coronary heart dis-
ease and stroke is examined. We expand the current knowledge on cardiovascular risk 
prediction with comparing the predictive performance of newer risk markers in coro-
nary heart disease risk prediction. Chapter 3.2 compares the added value of the three 
subclinical measures of atherosclerosis in coronary heart disease risk prediction with 
that of some emerging biomarkers. Chapter 3.3 goes one step further and addresses the 
differential ability of the three subclinical measures in prediction of various components 
of cardiovascular disease; coronary heart disease, heart failure, and stroke, and com-
pares them with some other newer biomarkers and markers of cardiac function that are 
presumed to be prognostic indicators for the cardiovascular disease. Following this top-
ic on the differential ability of subclinical measures in prediction of various components 
of cardiovascular disease, chapter 3.4 is dedicated to coronary artery calcifi cation as a 
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screening tool for cardiovascular disease. For the cardiovascular risk prediction studies 
described in this chapter, we use data from the population-based Rotterdam Study 16.
In the fourth chapter of this thesis, the recently modifi ed area of cardiovascular risk 
prediction in women is discussed. In chapter 4.1, we apply the newly introduced rec-
ommendations for improving cardiovascular risk prediction in women to the popula-
tion-based Rotterdam Study 16.
Finally, the general discussion (chapter 5), summarizes the main fi ndings of the stud-
ies included in this thesis and places them in a broader perspective, addresses the meth-
odological considerations, elaborates on potential clinical implications, and discusses 
the directions for future research. 
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Genome-Wide Association Studies of 
Subclinical Measures of Atherosclerosis
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Genome-Wide Association 
Study for Carotid Intima-Media 
Thickness and Carotid Plaque
SUMMARY
Background: Carotid intima-media thickness (cIMT) and plaque de-
termined by ultrasonography are established measures of subclini-
cal atherosclerosis that each predict future cardiovascular disease 
events.
Methods: We conducted a meta-analysis of genome-wide associa-
tion data in 31,211 participants of European ancestry from nine 
large studies in the setting of the Cohorts for Heart and Aging Re-
search in Genomic Epidemiology (CHARGE) Consortium. We then 
sought additional evidence to support our fi ndings among 11,273 
individuals using data from 7 additional studies. 
Results: In the combined meta-analysis, we identifi ed three genom-
ic regions associated with common cIMT and two different regions 
associated with the presence of carotid plaque (P<5×10−8). The as-
sociated SNPs mapped in, or near, genes related to cellular-signal-
ing, lipid metabolism, and blood pressure homeostasis and two of 
the regions were associated with coronary artery disease (P<0.006) 
in the CARDIoGRAM Consortium. 
Conclusions: Our fi ndings may provide new insight into pathways 
leading to subclinical atherosclerosis and subsequent cardiovascu-
lar events.
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INTRODUCTION
Coronary heart disease (CHD) and stroke rank among the leading causes of death in the 
industrialized world 1 and a signifi cant genetic component underlies both outcomes. 
These clinical events are often preceded by the development of subclinical atherosclero-
sis, typically a thickening of the artery wall due to deposition of cholesterol rich material 
in the arteries that supply blood to major organs 2. Generalized atherosclerosis results 
from endothelial dysfunction, infl ammation, abnormalities in lipoprotein metabolism 3, 
coagulation and fi brinolysis 4.
Measures of subclinical atherosclerosis, disease that occurs before symptoms are 
noted, are predictive of incident clinical events and can be detected non-invasively and 
with reasonable precision in population samples using high resolution ultrasound tech-
niques. Both cIMT and plaque, refl ecting a thickening of the carotid artery wall or the 
presence of large irregular arterial wall deposits, respectively, are established measures 
of subclinical atherosclerotic disease. While there may be variation in carotid ultrasound 
measurement techniques, multiple independent studies have established consistent as-
sociation of carotid phenotypes with coronary events and stroke in prospective studies 
of young, middle-aged, and older adults 5,6 and recent consensus prevention guidelines 
cite cIMT as a potentially useful measure for prediction 7. While there is a correlation 
between common cIMT and carotid plaque, common cIMT refl ects carotid artery wall 
thickening that may result from multiple vascular etiologies including hypertension and 
atherosclerosis, whereas carotid plaque is an indicator of the discrete occurrence of 
carotid atherosclerosis. Several recent studies provide evidence that carotid plaque is a 
better predictor of future cardiovascular disease risk than common cIMT 8-10. 
Numerous family studies established consistent evidence for moderate heritabilities 
for common cIMT, internal cIMT and carotid plaque. However, candidate gene stud-
ies have not found consistent associations between single nucleotide polymorphisms 
(SNPs) and cIMT 11, and genome-wide linkage scans completed to date have revealed 
only suggestive regions for common cIMT 12,13. We performed a genome-wide associa-
tion study (GWAS) of three measures of subclinical carotid atherosclerosis; common 
cIMT, internal cIMT, and plaque, in a sample of up to 31,211 participants from nine 
population-based studies. In addition, we followed-up our discovery fi ndings in a sec-
ond stage that included 11,273 participants from 7 independent studies.
METHODS
Our analyses were performed within the Cohorts for Heart and Aging Research in Ge-
nomic Epidemiology (CHARGE) Consortium 22, which includes fi ve large population-
based prospective cohort studies; the Aging Gene-Environment Susceptibility-Reykjavik 
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Study (AGES), the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular 
Health Study (CHS), the Framingham Heart Study (FHS), and the Rotterdam Study I 
(RS-I). Four additional community-based studies - the Old Order Amish (Amish) Study, 
the Erasmus Rucphen Family (ERF) Study, the SardiNIA Study, and the Study of Health 
in Pomerania (SHIP) - collaborated with CHARGE for these analyses. For all studies 
participating in the meta-analyses, each participant provided written informed consent 
and the Institutional Review Board at the parent institution for each respective study ap-
proved the study protocols.
Different cohorts used different ultrasound devices to assess cIMT or plaque. Most 
studies, calculated the ‘mean of the maximum IMT’ by averaging the maximum IMT 
of both the right and left CCA, near and far walls, or far wall only in some other stud-
ies. Carotid plaque defi nition included the presence of any plaque in most studies and 
stenosis greater than 25% in others. 
We performed a GWAS of three measures of subclinical carotid atherosclerosis; com-
mon cIMT, internal cIMT, and plaque, in a sample of up to 31,211 participants from the 
nine population-based studies that performed genome-wide genotyping with commer-
cial SNP arrays and imputed to the approximately 2.5 million autosomal SNPs in the 
Phase II HapMap CEU reference panel. In addition, we followed-up our discovery fi nd-
ings in a second stage that included 11,273 participants from 7 independent studies.
RESULTS
The cross-sectional discovery genome-wide analysis of carotid artery phenotypes in-
cluded 31,211 participants from nine community-based studies whose mean age 
ranged from 44 to 76 years. Characteristics of the samples are presented in Table 1. In 
the studies in which all three carotid measures were available, the correlations between 
common cIMT and plaque ranged from 0.27 to 0.39, and between common cIMT and 
internal cIMT, from 0.36 to 0.67.
The a priori threshold for genome-wide signifi cance was 5×10-8, and a p-value > 5×10-8 
but <4×10-7, corresponding to not more than one expected false positive fi nding over 
2.5 million tests, was considered suggestive evidence for association in our analyses.
Figure 1A provides a plot of -log10 (p-values) for the associations of the approximately 
2.5 million SNPs with common cIMT by chromosome and position for the meta-analysis 
of the nine discovery studies. P-values from the meta-analysis of plaque (n=25,179 
participants) are presented according to their genomic positions in Figure 1B. Overall, 
from the discovery meta-analysis of common cIMT and plaque, we carried forward 3 
genome-wide signifi cant SNPs and 5 suggestive SNPs to the second stage. Our second 
stage included 11,273 participants from seven community-based studies, six of which 
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Figure 1A. Genome-wide Manhattan plot for common carotid IMT
Figure 1B. Genome-wide Manhattan plot for presence of plaque
Figure 1. A–B: Genome-wide Manhattan plots for common cIMT and plaque
Plots show the individual p-values (based on discovery meta-analysis) against their genomic position 
for common carotid IMT (Figure 1A) and for the presence of plaque (Figure 1B). The dashed line indi-
cates the threshold for follow-up, p<4 ×10−7 and the solid line indicates the threshold for genome-wide 
signifi cance, p<5 ×10−8. The nearest genes are indicated above points that surpassed our genome-wide 
signifi cance threshold.
provided results for common cIMT (total N=10,403) and three of which provided results 
for plaque (N=6,013). 
Table 2A presents the genome-wide signifi cant association results for the discovery 
meta-analysis for common cIMT and plaque and Table 2B presents the results for the 
second stage and combined meta-analyses for common cIMT and plaque. 
We show the discovery GWAS results for the 100 kb region surrounding the signal 
SNPs for common cIMT and plaque along with the recombination rates and the known 
genes in that region in Figures 2 and 3.
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Figure 2. Regional plots for common carotid IMT SNPs
Figure 3. Regional plots for carotid plaque SNPs
Plots are centered on the most signifi cant SNP at each locus along with the meta-analysis results for 
SNPs in the 100kb region surrounding it. All SNPs are plotted with their discovery meta-analysis p-val-
ues against their genomic position, with the most signifi cant SNP in the region indicated as a diamond 
and other SNPs shaded according to their pairwise correlation (r2) with the signal SNP.
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Figures 4 and 5 show the study-specifi c fi ndings from the combined meta analyses of 
common cIMT and plaque, respectively. 
Common cIMT
For common cIMT, 3 independent loci achieved our genome-wide signifi cance thresh-
old (p<5×10-8) in the combined meta-analysis.
The strongest association was for rs11781551, found on 8q24 approximately 385 kb 
from ZHX2, where the A allele (allele frequency [AF]=0.48), was associated with lower 
common cIMT (ß=-0.0078, p= 2.4×10-11), i.e. a 0.8% lower mean common cIMT per 
copy of the A allele. The second association was for rs445925, located 2.3 kb from 
APOC1 on 19q13, a region that also includes APOE, APOC2, and APOC4. The G al-
lele (AF=0.11) was associated with lower common cIMT (ß=-0.0156, p=1.7× 10-8). The 
third association was for rs6601530, located within the PINX1 gene on 8q23.1. Each 
copy of the G allele (AF=0.45) was associated with higher common cIMT (ß=0.0078, 
p=1.7×10-8). We also identifi ed a suggestive locus, marked by rs4712972 near the 
SLC17A4 gene on 6p22, where the A allele was associated with higher common cIMT 
(ß=0.0099, p= 7.8×10-8).
While our genome-wide signifi cant and suggestive SNPs from combined meta-analy-
ses for common cIMT explained a small proportion of the trait variance (up to 1.1%), we 
further constructed an additive genetic risk score (0–8 alleles) comprised of the number 
of common cIMT risk alleles at the four loci. In the discovery samples, the additive risk 
score showed graded increasing association with common cIMT across all studies with 
an average increase of 9.5% in common cIMT from the lowest (0–2) to the highest (6–8) 
risk category.
Plaque
In analysis of carotid artery plaque, 2 independent loci achieved the genome-wide sig-
nifi cance threshold (p<5×10-8) in the combined meta-analysis.
The most signifi cant signal was observed for rs17398575, situated 96.5 kb from the 
PIK3CG gene on 7q22. Per copy of the T allele (AF=0.25), we observed an 18% in-
creased odds of presence of plaque (p=2.3×10-12). The second signal was centered at 
rs1878406, located 8.5 kb from EDNRA on 4q31. Each copy of the T allele (AF=0.13) 
was associated with a 22% increased odds of the presence of plaque (p=6.9×10-12). Fur-
thermore, two SNPs showed suggestive evidence for association in our combined meta-
analysis. The fi rst suggestive locus was rs17045031 on 3p13 where each copy of the A 
allele was associated with decreased odds of the presence of plaque (p=1.0×10-7). Our 
second suggestive locus was rs6511720, near LDLR on 19p13. Per copy of the T allele 
we observed a decreased odds of the presence of plaque (P=3.8×10-7).
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Figure 4. Forest plots for common carotid IMT SNP associations
Plots show the study-specifi c association estimates (ß) and 95% confi dence intervals for the nine 
discovery and second stage studies, presented as bars. The scale is ln(cIMT). The association esti-
mate and confi dence interval for the meta-analysis combining discovery and second stage results 
is presented as a diamond. Blank spaces indicate occasions in which a particular study was not 
able to provide results for a given SNP.
Figure 5. Forest plots for carotid plaque SNP associations
Plots show the study-specifi c association estimates (OR) and 95% confi dence intervals for the 
nine discovery and second stage studies, presented as bars. The association estimate and confi -
dence interval for the meta-analysis combining discovery and second stage results is presented 
as a diamond. Blank spaces indicate occasions in which a particular study was not able to 
provide results for a given SNP.
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For both cIMT and plaque, secondary discovery genome-wide meta-analyses condi-
tioned on the genome-wide signifi cant and suggestive SNPs from the combined meta-
analyses did not reveal any additional associations.
Internal cIMT
No SNP achieved our signifi cance threshold for follow up in the discovery analyses of 
internal cIMT. Results for internal cIMT SNPs are not shown. 
Cross-Phenotype Comparisons
We also examined the genome-wide signifi cant and suggestive SNPs from our combined 
meta-analyses for common cIMT and plaque across the three carotid phenotypes. The 
directions of association were generally consistent and three SNPs, rs445925 (APOC1) 
from the common cIMT analysis and rs17398575 (PIK3CG) and rsrs1878406 (EDNRA) 
from the plaque analysis, were associated with all three phenotypes (p<0.05/8/2=0.003) 
in cross-phenotype comparisons.
Associations with Coronary Artery Disease
We investigated the genome-wide signifi cant and suggestive SNPs from our combined 
meta-analyses for common cIMT and plaque for their potential associations with coro-
nary artery disease (CAD) in the CARDIoGRAM Consortium (Table 3). Two SNPs from 
our plaque analysis had a p-value for association with CAD less than 0.006 (0.05/8 
tests). The fi rst, rs6511720, near LDLR, where the G allele was associated with both 
higher plaque risk in our study and higher CAD risk (p=0.0002); and rs1878406, near 
EDNRA where the C allele was associated with lower risk of plaque and lower risk 
of CAD (p=2×10-6). One SNP from common cIMT analysis, rs445925 near APOC1, 
showed a suggestive association with CAD with the same allele (A) being associated 
with higher common cIMT and higher CAD risk (p=0.02). Another SNP identifi ed in the 
plaque analysis, rs17045031 near LRIG1, showed a suggestive association with CAD, 
with the G allele associated with both lower odds of plaque and lower risk of CAD 
(p=0.04).
Conversely, none of SNPs reported to be associated with coronary artery disease in 
the CARDIoGRAM Consortium 14 had a signifi cant association (i.e., a p-value less than 
0.00072, a conservative Bonferroni correction for 23 tests across three phenotypes) 
in our discovery meta-analyses of common cIMT, internal cIMT, or plaque (data not 
shown).
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DISCUSSION
In this meta-analysis of GWAS data from nine studies of common cIMT and seven stud-
ies of plaque, we identifi ed genome-wide signifi cant associations between 3 regions 
and common cIMT and between 2 regions and the presence of carotid plaque in over 
40,000 participants of European ancestry. Interestingly, EDNRA one of our genome-
wide signifi cant regions in the combined meta-analysis of plaque was related to mul-
tiple carotid phenotypes and was also associated with coronary artery diseases in the 
recent large meta-analysis by the CARDIoGRAM Consortium.
Three SNPs emerged as genome-wide signifi cant from our combined meta-analysis 
of common cIMT. The strongest association, on chromosome 8 (rs11781551), is an in-
tergenic SNP located 385 kb from the ZHX2 gene. Members of this gene family are nu-
clear homodimeric transcriptional repressors that interact with the A subunit of nuclear 
factor-Y (NF-YA) and contain two C2H2-type zinc fi ngers and fi ve homeobox DNA-
binding domains. Little information about these proteins exists regarding cardiovascular 
disease or population studies.
A second association, on 19q13 (rs445925), fell upstream of the APOC1 gene. While 
this region has been of interest for its role in neurological genetics because of the APOE 
gene, it is also been frequent candidate gene for cardiovascular disease traits 15. Al-
though some previous studies have found associations of variation at the APOE locus 
and common cIMT 16, among 4 of our discovery studies that had independently mea-
sured the APOE epsilon variants, the correlation between rs445925 and the e4 allele 
was less than 0.05. Further, models that included both the APOE e4 and the APOC1 
variant indicated that the APOE gene was not associated with common cIMT in these 4 
studies (data not shown), while the APOC1 variant still showed a signifi cant association 
with common cIMT. While APOE variants have been implicated in cases of familial dys-
lipidemia and premature atherosclerosis and in recent genome-wide association studies 
with variation in multiple lipoprotein measures 17, our results suggest that APOC1 is the 
primary variant of interest for carotid traits.
The third association (rs6601530) was located in an intron of the Pin2-interacting 
protein 1 (PINX1) gene. The protein, a telomerase inhibitor 18 that plays a role in chro-
mosomal segregation in mitosis 19, has been investigated in relation to cancers, but was 
not considered a candidate gene for cardiovascular phenotypes. 
The region on chromosome 6 marked by rs4712972, which includes the SLC17A4, 
SLC17A1, and SLC17A3 genes showed suggestive evidence for association with com-
mon cIMT in our combined meta-analysis. This region may merit further investigation as 
recent genome-wide association studies have implicated this region with uric acid lev-
els 20,21. Although high uric acid levels have been associated with cardiovascular disease 
and all cause mortality 22, the contribution to atherosclerotic vascular disease remains 
controversial 23.
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Plaque Associations
For plaque, two regions were genome-wide signifi cant in our combined meta-analysis. 
The fi rst region was within 100kb of the PIK3CG gene, which encodes one of the pi3/
pi4-kinase family of proteins. These proteins are important modulators of extracellular 
signals, including those elicited by E-cadherin-mediated cell-cell adhesion, which plays 
an important role of endothelin in maintenance of the structural and functional integrity 
of epithelia. The fact that this region was reported as a top hit in a recent GWAS of both 
platelet volume 24 and aggregation 25 suggests pleiotropy and highlights the intercon-
nectedness of multiple cardiometabolic traits.
The second genome-wide signifi cant region was near the EDNRA gene. Because of 
the role of endothelin as a potent vasoconstrictor, the endothelin receptor, type A is a 
target for pharmacologic treatments to reduce blood pressure 26. In addition, variation 
in the gene was associated with blood pressure 27, atherosclerosis 28, and cardiovascular 
disease endpoints 29 in candidate gene studies.
Two more regions showed suggestive evidence for association in our combined meta-
analysis for plaque. The fi rst region, near the LDLR gene is a particularly interesting can-
didate for subclinical atherosclerosis because of its role in familial hypercholesterolemia 
and its appearance in recent genome-wide association studies for lipid traits 30-33 and 
myocardial infarction 14,34. Notably, the LDLR SNP recently reported to be associated 
with MI (rs1122608) is located 38 kb away and is in modest LD (r2=0.2 in HapMap 
CEU) with the signal SNP (rs6511720) in our analysis that also showed an association 
with CAD in the CARDIoGRAM Consortium. The second was in the vicinity of LRIG1, 
which negatively regulates growth factor signaling and is involved in the regulation of 
epidermal stem cell quiescence.
Interestingly, we found three loci (APOC1, PIK3CG, and EDNRA) that were associ-
ated with all three carotid phenotypes. Among these, the EDNRA locus was also sig-
nifi cantly associated with coronary artery disease in the recent large meta-analysis by 
the CARDIoGRAM Consortium. These associations may provide important insights into 
the pathophysiological mechanisms relating the genes to atherosclerosis and subse-
quent coronary artery disease. In particular, the concordance of association with SNPs 
in EDNRA with both carotid plaque and CHD suggests a common etiology for subclini-
cal and clinically apparent disease that warrants further investigation.
The strengths of the current study include the large sample size, the population-based 
designs, the collaboratively designed pre-specifi ed analysis plan, and the high quality 
of both genotyping and phenotyping. Further, our ability to relate our fi ndings to the 
outcome of CAD in a large independent meta-analysis provides important additional 
context to our results. These associations are unlikely to be due to population stratifi ca-
tion since the discovery sample was restricted to whites of European origin and was also 
investigated for global latent population substructure.
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The study also has limitations. A single cross-sectional IMT assessment was used in 
all studies and ultrasound protocols varied across participating studies. For example, 
plaque defi nition included the presence of any plaque in most studies and stenosis 
greater than 25% in others. The heterogeneity of measurement techniques may have 
compromised our ability to detect small associations. Despite this heterogeneity, the 
ability to detect consistent genetic associations for several carotid measures suggests 
that additional signals may be discovered in future studies utilizing a larger sample size 
or a higher resolution technique such as magnetic resonance imaging. Further, few stud-
ies had internal cIMT measures since these are more diffi cult to obtain than common 
cIMT measurements and thus limited our ability to discover associations with this phe-
notype. Although our sample size was reasonably large, we still had limited power to 
detect associations with small effect sizes. Genome-wide association studies are known 
for revealing associations with common variants and may miss rare variants not covered 
by the commercial genotyping arrays. For instance, the sparse coverage of the APOC1 
and LDLR gene regions resulted in varying imputation quality and a lower effective 
sample size for the analysis of these two regions.
Because we did not conduct follow-up fi ne mapping of the results, and because some 
SNPs were distant from known genes, it is likely that the identifi ed SNPs are not caus-
al variants, but, instead, may be in linkage disequilibrium with variants that were not 
analyzed. Because some of our associations attained genome-wide signifi cant p-values 
only in the combined meta-analysis, confi rmation of our fi ndings in other populations 
and further exploration of these genomic regions with dense genotyping, expression, 
and translational studies will be required to better understand the role of these genes in 
subclinical atherosclerotic disease.
In summary, our meta-analysis of GWAS data from nine community-based studies 
has revealed 5 new loci for common cIMT and plaque. These loci implicate LDL me-
tabolism (APOC1), endothelial dysfunction (EDNRA), platelet biology (PIK3CG), and 
telomere maintenance (PINX1). Two of our identifi ed loci are also associated with coro-
nary artery disease in the recent large meta-analysis by the CARDIoGRAM Consortium. 
Exploring the molecular, cellular and clinical consequences of genetic variation at these 
loci may yield novel insights into the pathophysiology of clinical and subclinical car-
diovascular disease.
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3.1
Carotid Intima-Media Thickness 
in Cardiovascular Risk 
Stratifi cation
SUMMARY
Background: Non-invasive measures of atherosclerosis, such as ca-
rotid intima-media thickness (cIMT), may improve global cardio-
vascular risk prediction. The aim of this study was to determine 
whether common cIMT in addition to traditional risk factors im-
proves risk classifi cation in a general population of older people.
Methods: A group of 3,580 non-diabetic people aged 55-75 years 
and free of cardiovascular disease at baseline were followed for a 
median time of 12.2 years. Compared to models based on Framing-
ham risk factors, we studied the ability of common cIMT measure-
ment to better classify people into categories of low (<10%), inter-
mediate (10-20%) and high (>20%) 10-year risk of hard coronary 
heart disease (CHD) and stroke. 
Results: In older men, addition of cIMT to Framingham risk factors 
did not improve prediction of hard CHD or stroke. In older women, 
addition of cIMT to Framingham risk factors signifi cantly improved 
risk classifi cation. cIMT improved the C-statistic of the model for 
hard CHD from 0.711 to 0.719 and for stroke from 0.712 to 0.721, 
at good calibration. Reclassifi cation was least in the majority of 
women classifi ed as low risk for hard CHD (4%, n=76) and for 
stroke (3%, n=62) and most substantial in women at intermediate 
risk for hard CHD (43%, n=70) and for stroke (28%, n=76). The 
net reclassifi cation improvement in women was 8.2% (P=0.03) for 
hard CHD and 8.0% (P=0.06) for stroke.
Conclusions: cIMT had some additional value beyond traditional 
risk factors in the cardiovascular risk stratifi cation of older women, 
but not of older men.
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INTRODUCTION
Cardiovascular disease (CVD) is the major cause of morbidity and premature death in 
the Western world. The underlying atherosclerosis develops over many years and symp-
toms usually do not occur until the disease is already at an advanced stage. The majority 
of CVD is related to modifi able risk factors and modifi cation of these factors has been 
shown to reduce CVD morbidity and mortality 1.
The current, clinically accepted concept of matching treatment intensity to the degree 
of cardiovascular risk suggests that it is important to identify the most accurate ap-
proach to risk stratifi cation as a solid base for the best treatment strategies in people at 
risk of CVD. In accordance with current guidelines, global risk factor assessment using 
algorithms such as the SCORE risk chart 2 or Framingham Risk Score 3 are increasingly 
used to stratify people in categories of low, intermediate, and high risk, based on 10-
year absolute risk of CVD or coronary heart disease (CHD). However, these risk factor 
algorithms are of limited accuracy, especially in women and the elderly 4,5. To improve 
risk stratifi cation, expert panels have proposed non-invasive measures predicting ath-
erosclerotic disease, such as carotid intima-media measurement (cIMT), to complement 
the risk stratifi cation based on traditional risk factors 1,3,6,7. Previous studies have shown 
that the addition of a cIMT measurement to established risk factors leads to small and 
sometimes signifi cant improvements in cardiovascular risk prediction by means of in-
creases in the C-statistic 8. However, in the evaluation of the clinical value of a new test, 
it is important to assess the reclassifi cation of individuals into different risk categories 
when the new test is added to traditional risk factors 9; to date limited research has ad-
dressed this issue 10,11.
In the population-based Rotterdam study, we stratifi ed non-diabetic men and women 
of 55–75 years who were free of CVD at baseline into three widely used clinical risk 
categories of low (<10%), intermediate (10-20%) and high (>20%) 10-year risk of hard 
CHD and stroke based on Framingham risk factors and studied the ability of common 
cIMT to reclassify people to a more accurate risk category.
METHODS
Study Population
The study was embedded in the Rotterdam Study, which is a prospective, population-
based study among subjects aged 55 years and older in a municipality of Rotterdam that 
started in 1990. The rationale and design of the Rotterdam Study has been described 
elsewhere 12,13. The baseline examination took place from 1990 to 1993. Of the 7,983 
participants (response rate 78%), 5,643 underwent a common cIMT measurement.
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Missing cIMT measurements were due to restricted availability of ultrasonographers. 
In line with current guidelines for cardiovascular screening 3, we excluded people of 75 
years and older (n=1,302) and people already defi ned as being at high cardiovascular 
risk based on having diabetes (N=431) or established cardiovascular disease (CVD) at 
baseline (N=330).
Prevalent CVD was defi ned as a history of clinically manifest myocardial infarction, 
coronary artery bypass grafting, percutaneous coronary intervention, stroke, symptom-
atic peripheral artery disease (PAD), aortic or carotid surgery. Hence, the current analy-
sis was carried out in 3,580 asymptomatic individuals. The Medical Ethics Committee 
of Erasmus Medical Center approved the study, and all participants gave informed con-
sent.
Common Carotid IMT Measurement
Ultrasonography of both carotid arteries was performed with a 7.5MHz linear array 
transducer and a duplex scanner (ATL UltraMark IV; Advanced Technology Laboratories). 
Measurements of the common carotid artery (CCA) intima-media thickness involved a 
length of 10mm distal of the bulb. cIMT was determined as the average of mean, near- 
and far-wall IMT, providing the average of left and right arteries. The procedure has been 
described in detail previously 14.
Cardiovascular Risk Factors
Information on cardiovascular risk factors was acquired during the baseline examination 
as described previously 15. Diabetes was defi ned as a non fasting glucose> 11 mmol/l 
and/or use of anti-diabetic medication.
Clinical Outcomes
The follow-up procedures of the Rotterdam Study have been reported previously 15. 
None of the people considered for analysis was lost to follow up. As outcome, we used 
hard CHD; consisting of incident myocardial infarction (MI) and coronary heart dis-
ease mortality, and stroke; which included ischaemic stroke (mortality). If a person died 
within 4 weeks of an MI or ischaemic stroke, events were coded as fatal. Follow up was 
completed by January 2005. 
Statistical Analysis 
Common cIMT and Risk of CVD 
We used Cox proportional hazard regression analysis to estimate the hazard ratio (HR) 
of a 1-standard deviation increase of cIMT to predict hard CHD and stroke for the total 
population and as well as stratifi ed by gender. In the analysis, we corrected for age and, 
if appropriate, gender. We additionally adjusted for current smoking, total cholesterol, 
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HDL cholesterol, systolic blood pressure and use of antihypertensive medication, and 
for atrial fi brillation for the stroke outcome. We used log minus log plots to check for 
proportionality of hazards over time and found no indications of violation of the pro-
portionality assumption. 
Risk Prediction Models
We used Cox proportional hazard regression analysis to derive estimates of individu-
al 10-year risk of hard CHD and stroke. Analyses were performed by gender. For the 
outcome hard CHD, we used the same predictors as defi ned in the Framingham risk 
score, in accordance with the ATP III guidelines 3. The model thus included age, gen-
der, systolic blood pressure, use of antihypertensive medication, total cholesterol, HDL 
cholesterol and current smoking (model 1). For the outcome stroke, model 1 also in-
cluded atrial fi brillation, in line with the Framingham stroke risk score 16. In a second 
step, we extended model 1 with common cIMT (model 2). Both models were fi tted to 
the gender-specifi c subsets of the Rotterdam Study data. We used restricted cubic spline 
transformations with four knots for continuous variables in the models, four knots being 
a good compromise between fl exibility and loss of precision caused by over-fi tting of 
the model 17. We used the likelihood ratio test to study the null-hypothesis of no effect of 
common cIMT to predict hard CHD and stroke beyond Framingham risk predictors. To 
examine the discriminative ability of the two models, we calculated the bootstrap cor-
rected C-statistic using 150 repetitions for both gender-specifi c models. The purpose of 
using the bootstrap method is to correct for over-optimism of the fi tted models 18. Next, 
we computed reclassifi cation percentages to study the incremental ability of common 
cIMT to classify subjects in risk categories according to commonly used categories of 
10-year hard CHD and stroke risk: low (<10%), intermediate (10–20%), and high risk 
(>20%) 3. Observed 10-year risk of CVD was estimated by Kaplan-Meier survival analy-
sis for each cell of the reclassifi cation table to show calibration of reclassifi ed people 
with observed risk. To evaluate true improvement in classifi cation by addition of com-
mon cIMT to the Framingham model we calculated the net reclassifi cation improve-
ment (NRI) 19.
In secondary analyses, we repeated the prediction analyses using the mean of the 
maximum of IMT values of near and far walls of both common carotid arteries as a 
determinant instead of the mean of the mean IMT values. 
Covariables were missing in less than 2% of people. We used single imputation by 
the Expectation Maximization method. All analyses were performed using SPSS for Win-
dows (SPSS, Inc., Chicago, Illinois, USA) and R version 2.7.2. (R Foundation for Statisti-
cal Computing, Vienna, Austria).
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RESULTS
Baseline characteristics of men and women are shown in Table 1. The total population 
of 3,580 people consisted of 1,398 men and 2,182 women (61%). Median follow-
up duration (inter-quartile range) was 12.2 (11.7–13.1) years. During this period, 530 
events occurred of which 267 were in men and 263 in women. One hundred and six 
men and 68 women had a myocardial infarction, 89 men and 118 women had an 
ischaemic stroke whereas 60 men and 59 women died of CHD and 12 men and 18 
women had a fatal ischaemic stroke.
For the risk of hard CHD, the age- and gender adjusted hazard ratios (95% CI) for a 
1-standard deviation increase in common cIMT in the total population was 1.26 (1.13–
1.41) and decreased to 1.16 (1.03–1.30) after additional adjustment for the remaining 
cardiovascular risk factors. Corresponding risks of stroke were: 1.33 (1.18–1.50) and 
1.25 (1.10–1.42). In gender specifi c subsets, the analogous hazard ratios for the out-
come hard CHD were 1.08 (0.92–1.27) and 1.02 (0.86–1.20) in men and 1.56 (1.34–
1.81) and 1.40 (1.19–1.65) in women. For stroke outcome, corresponding hazard ratios 
were 1.28 (1.07–1.54) and 1.18 (0.97–1.43) in men and 1.38 (1.18–1.62) and 1.32 
(1.12–1.56) in women.
In hard CHD risk prediction in men, addition of common cIMT did not improve 
model performance of the refi tted Framingham risk model. The likelihood chi-square 
of model 2 did not signifi cantly increase compared to model 1 (P=0.84). Hence, the 
Table 1. Baseline characteristics of the population, by gender
Variable Men N = 1,398 Women N = 2,182 P Value 
Age (years) 64.5±5.3 64.8±5.6 0.068
Body mass index (kg/m2) 25.7±2.9 26.6±3.9 <0.001
Current smoking (%) 30.3 22.5 <0.001
Systolic blood pressure (mmHg) 137±22 136±22 0.072
Diastolic blood pressure (mmHg) 76±12 73±11 <0.001
Antihypertensive treatment (%) 10.2 15.7 <0.001
Total cholesterol (mmol/L) 6.4±1.1 6.9±1.2 <0.001
HDL cholesterol (mmol/L) 1.2±0.3 1.5±0.4 <0.001
Lipid lowering medication (%) 1.5 2.2 0.137
Antithrombotic medication (%) 3.6 1.4 <0.001
Atrial fi brillation (%) 2.9 2.0 0.113
Common cIMT (mm) 0.82±0.14 0.77±0.12 <0.001
HDL, high-density lipoprotein; IMT, intima-media thickness. Values are mean (±standard deviation) for 
continuous variables and percentages for dichotomous variables. 
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C-statistic did not improve by addition of cIMT: 0.611 (model 1) and 0.610 (model 2). 
In contrast, addition of common cIMT signifi cantly improved model performance in 
women. The likelihood chi-square increased by 15.2 points (P<0.001). The C-statistic 
improved from 0.711 to 0.719, indicating slightly better average discriminative ability 
of the model including cIMT.
In stroke risk prediction in men, addition of common cIMT did not improve model 
performance of the refi tted Framingham risk model. The likelihood chi-square did not 
signifi cantly increase (P=0.11), the C-statistic slightly improved by addition of cIMT from 
0.692 (model 1) to 0.698 (model 2). In women, the likelihood chi-square increased by 
10.0 points (P=0.002). The C-statistic improved from 0.712 to 0.721.
Table 2 displays categories of estimated 10-year hard CHD risk based on the Framing-
ham risk model before and after adding common cIMT in men and women. In men, 
percentages in the low, intermediate and high-risk categories were 53%, 43% and 4%, 
respectively. For women these percentages were 92%, 7% and 1%. In accordance with 
the fi nding that addition of cIMT did not improve the C-statistic of the Framingham risk 
model, additional cIMT measurements led to hardly any reclassifi cation among men. 
Correspondingly, the net reclassifi cation improvement (NRI) was 0.21% (P=0.50) for 
men. In women, additional cIMT measurement led to more reclassifi cation. Of women 
at low risk, 4% (n=73) reclassifi ed to the intermediate risk category and three women to 
high risk. Of women at intermediate risk, 35% (n=57) were downgraded to low risk and 
8% (n=13) upgraded to high risk. Of women at high risk, 29% (n=4) were downgraded 
to the intermediate risk category. Addition of common cIMT in women led to a net gain 
in reclassifi cation of 9.1% in people with an event and a net decline in reclassifi cation 
of 0.9% in people without event, resulting in a NRI of 9.1–0.9=8.2% (P=0.03).
Table 3 displays categories of estimated 10-year stroke risk based on the Framingham 
risk model before and after adding common cIMT in men and women for the out-
come of stroke. In men, percentages in the low, intermediate and high-risk categories 
were 85%, 13% and 2%, respectively. For women corresponding percentages were 
87%, 12% and 1%. In men, more reclassifi cation was observed compared with the 
outcome of stroke. However, this was not clinically signifi cant, by means of the NRI 
(3.9%; P=0.16). Of women at low risk, 3% (n=59) of people reclassifi ed to the interme-
diate risk category and three people to high risk. Of women at intermediate risk, 19% 
(n=51) were downgraded to low risk and 9% (n=25) upgraded to high risk. Of women 
at high risk, 37% (n=10) were downgraded to the intermediate risk category. Addition 
of common cIMT in women led to a net gain in reclassifi cation of 9% in people with an 
event and a net decline in reclassifi cation of 1% in people without event, resulting in 
a NRI of 9.0–1.0=8% (P=0.06). Repeating the analyses using the mean of the maximal 
cIMT values of near and far walls did not lead to substantial changes in reclassifi cation 
percentages and NRI values (data not shown). 
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Generally, point estimates of the observed risks agreed with the corresponding cat-
egories of predicted risk indicating good calibration, except for cells containing small 
numbers.
DISCUSSION
This population-based study shows that the addition of common cIMT measurement to 
the Framingham risk model does not signifi cantly improve the risk prediction of hard 
CHD and stroke in older men and only modestly improves risk classifi cation for these 
outcomes in older women. Most substantial reclassifi cation was observed in women 
classifi ed as intermediate risk based on traditional risk factors. Of the women classifi ed 
as being at intermediate risk for hard CHD (7% of all women), cIMT measurement re-
classifi ed 35% of people to low and 8% to high-risk categories. The net reclassifi cation 
improvement was 8.2% (P=0.03) for the total population of women. Of the women clas-
sifi ed as being at intermediate risk for stroke (12% of all women), cIMT measurement 
reclassifi ed 19% of people to low and 9% to high-risk categories. The net reclassifi ca-
tion improvement for the total population of women was 8% (P=0.06).
CIMT and Future Cardiovascular Disease
An essential prerequisite for the use of cIMT in cardiovascular risk stratifi cation is its abil-
ity to predict future cardiovascular events. A meta analysis by Lorenz et al. 20 comprising 
eight large, longitudinal population- based cohort studies showed that common cIMT is 
a strong predictor of MI and stroke in the total population. The overall age- and gender-
adjusted estimates of relative risk per 1-standard deviation increase of cIMT reported 
in this meta-analysis were 1.26 (1.21–1.30) for MI and 1.18 (1.16–1.21) for stroke. In 
line with these results, the corresponding estimates we found for hard CHD and stroke 
risk in the total population were 1.26 (1.13–1.41) and 1.33 (1.18–1.50). We found that 
associations were stronger in women than in men. All associations were attenuated by 
additional adjustments for cardiovascular risk factors.
Additional Value of cIMT in Cardiovascular Risk Prediction
The Atherosclerosis Risk in Communities (ARIC) study 10 recently reported on the ad-
ditional value of cIMT and plaque beyond traditional risk factors in the 10-year risk 
prediction of CHD. In contrast to our results, this study found a higher additional value 
of cIMT in men than in women. The addition of cIMT beyond traditional risk factors 
resulted in a signifi cant increase in C-statistic from 0.742 to 0.750 in men and a non-
signifi cant increase from 0.759 to 0.762 in women. The NRI was 8.9 (3.4–15.1) for men 
and 6.1 (-2.3–9.4) for women. Unfortunately, reclassifi cation percentages for addition 
of cIMT were not presented. The discrepancy in the results between the ARIC and our 
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study might be explained at least partly by the fact that their study population was 
younger (mean age 54 versus 65 years). Since IMT is thought to represent an early stage 
of atherosclerosis 21, it may be possible that the additional value of IMT diminishes with 
advancing stages of atherosclerosis, which would particularly affect older men. Another 
possible explanation for not fi nding an additional value of IMT in older men might be 
that people prone to the effects of atherosclerosis already died before study inclusion 
or developed a cardiovascular event that was one of the exclusion criteria of our study. 
Since men develop atherosclerosis at an earlier age than women, this selection would 
have greater impact on our male than on our female study population. Differences in 
results might also be related to the fact that the ARIC study used total CHD as an out-
come, which included revascularizations and silent MI while we studied hard CHD 
only. Both studies calculated the mean cIMT of near and far wall and measured IMT in 
the distal common carotid artery (CCA). However, in extent, the ARIC study also took 
the IMT in the carotid artery bifurcation and the proximal internal carotid arteries into 
account. Despite the differences in results between the two studies, it is of note that in 
both the ARIC and our study the observed additional value of IMT seems to be modest. 
A recent publication by the Carotid Atherosclerosis Progression Study (CAPS) group 
reported that in 4,904 individuals free of CVD at baseline (mean age 50 years, 48% 
male), carotid intima media thickness was signifi cantly and independently predictive 
for cardiovascular events. However, for the outcome of myocardial infarction, addition 
of common cIMT to a model using the Framingham risk factors led to a small increase 
in C-statistic from 0.732 to 0.741 and only 25 people (0.6%) were reclassifi ed. The 
net reclassifi cation improvement was 0.14% (P=NS). Analyses including other endpoint 
defi nitions (angina/MI/all-cause mortality), other carotid segments (carotid bifurcation/
internal carotid artery), and the SCORE risk model for baseline prediction did not result 
in consistently better risk prediction with cIMT. The fact that the mean age and thereby 
the mean cIMT (0.72 mm) was relatively low might have played a role in the negative 
fi ndings. Furthermore, the assessment of clinical events was based on health insurance 
data and questionnaires that could have led to misclassifi cation of the outcome and 
underestimation of the additional effect of cIMT 11. A systematic review of studies in 
people free from CVD reported that the addition of a cIMT measurement to established 
risk factors led to small and sometimes signifi cant improvements in cardiovascular risk 
prediction by means of increases in the C-statistic 8. 
The number of women upgraded in risk exceeded that of women downgraded in risk 
– 4.0% (n=89) versus 2.8% (n=61) for hard CHD and 2.0 % (n=43) versus 1.4% (n=31) 
for stroke (Tables 2 and 3). This suggests that the addition of cIMT measurement would 
lead to more women needing to receive medical therapy according to current preven-
tion guidelines 1,3. 
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In conclusion, despite the well-established association between cIMT and risk of fu-
ture CHD and stroke, accruing evidence indicates at best a modest benefi t of additional 
cIMT in the prediction of cardiovascular disease.
Strengths and Limitations
In order to appreciate the results, the strengths and limitations of the present study need 
to be considered. Strengths of our study include a large population-based cohort, in 
whom standardized measurements of risk factors and common cIMT measurement are 
performed. Furthermore, the complete and long follow-up has generated a large num-
ber of events enabling us to use hard events as an outcome and separate the analyses 
by gender. However, some limitations also need to be addressed. Firstly, while previous 
research within the Rotterdam study 22 showed that application of the Framingham Risk 
Score led to systematic overestimation of CHD risk in men, we chose to fi t a model 
based on Framingham risk factors to stratify our population in the well-known risk cat-
egories. A potential drawback is over-fi tting of the model, which could lead to under-
estimation of the additional value of cIMT measurement. However, all C-statistics were 
corrected for over-fi tting using the bootstrap method. Secondly, we used the mean of 
mean IMT values of near and far walls of both common carotid arteries in our analyses. 
However, when we used the mean of the maximal cIMT values of near and far walls, re-
classifi cation percentages and NRI values did not change substantially (data not shown). 
Thirdly, since usage of risk-modifying therapy, other than antihypertensive medication, 
is not accounted for in the Framingham risk model, the cardiovascular risk of people on 
this treatment might have been overestimated. However, at baseline few people used 
cholesterol-lowering medication or antithrombotic therapy (Table 1). Therefore, it is not 
likely that usage of these agents will have biased our results. Finally, our study was per-
formed in older people. The predictive power of traditional cardiovascular risk factors 
decreases with age while increased cIMT can be seen as a cumulative measure of the 
effect of lifetime exposure to cardiovascular risk factors on the arterial vessel wall and 
may therefore improve risk stratifi cation particularly at older age. This implies that our 
results should not automatically be generalized to a younger population.
CONCLUSIONS
Despite a well-established association between cIMT and risk of future CVD events, the 
additional predictive value of a cIMT measurement within clinical risk categories based 
on traditional risk factors seems to be limited. In older men, common cIMT measure-
ment did not signifi cantly improve risk stratifi cation based on traditional risk factors. In 
older women, common cIMT showed a modest ability to reclassify people to a more 
accurate cardiovascular risk category.
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3.2.1
Evaluation of Newer Risk Markers 
for Coronary Heart Disease Risk 
Classifi cation
SUMMARY
Background: Whether newer risk markers for coronary heart dis-
ease (CHD) improve CHD risk prediction remains unclear.
Methods: We assessed whether newer risk markers for CHD risk 
prediction and stratifi cation improve Framingham risk score (FRS) 
predictions among 5,933 asymptomatic participants (69.1 ± 8.5 
years) from the prospective population-based Rotterdam Study. The 
newer CHD risk markers included N-terminal fragment of prohor-
mone B-type natriuretic peptide (NT-proBNP), von Willebrand fac-
tor antigen, fi brinogen, chronic kidney disease, leukocyte count, C-
reactive protein, homocysteine, uric acid, coronary artery calcium 
[CAC] scores, carotid intima–media thickness, peripheral arterial 
disease, and pulse wave velocity.
Results: Adding CAC scores to the FRS improved the accuracy of 
risk predictions (c-statistic increase, 0.05 (0.02-0.06); net reclas-
sifi cation index, (NRI) 19.3% overall [39.3% in those at intermedi-
ate risk]). NT-proBNP also improved risk predictions but to a lesser 
extent (c-statistic increase, 0.02 (0.01 t-0.04); NRI, 7.6% overall 
[33.0% in those at intermediate risk]). Improvements in predictions 
with other newer markers were marginal.
Conclusion: Among 12 CHD risk markers, improvements in FRS 
predictions were most statistically and clinically signifi cant with 
the addition of CAC scores. Further investigation is needed to assess 
whether risk refi nements using CAC scores lead to a meaningful 
change in clinical outcome. Whether to use CAC score screening as 
a more routine test for risk prediction requires full consideration of 
the fi nancial and clinical costs of performing versus not performing 
the test for both persons and health systems.
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INTRODUCTION
Clinical decision making for detection, management, and prevention of coronary heart 
disease (CHD) relies on accurate risk assessment. The Framingham risk score (FRS) is 
the most commonly used CHD risk prediction instrument in clinical settings 1 and con-
stitutes the basis for the Adult Treatment Panel III guidelines for cholesterol-lowering 
therapy 2. Since validation of the FRS, many coronary risk factors, also called risk mark-
ers, have been identifi ed. Efforts are ongoing to assess the increment in risk prediction 
accuracy, if any, that these newer risk markers contribute to the FRS and other standard 
risk-scoring systems 3-15.
Recent guidelines recommend that several measures be used for assessing the incre-
ment in risk prediction accuracy offered by newer risk markers 16, but few studies have 
implemented those recommendations and none has used them to compare multiple 
markers within the same cohort 5-8,10,11,13-15. Use of only some of the recommended as-
sessment methods may provide misleading impressions of the clinical utility of novel 
markers in CHD risk prediction 17,18.
Therefore, we sought to compare the change in the accuracy of risk predictions when 
newer risk markers representative of various pathophysiologic pathways, including sev-
eral subclinical measures of atherosclerosis, were added to the established clinical risk 
predictors. To that end, we implemented the recent methods recommended for assess-
ment of risk prediction models 19,20. These assessments were performed in a community-
dwelling population and in a subpopulation at intermediate risk for CHD, in whom an 
increase in accuracy of risk predictions may be most clinically relevant.
METHODS
Study Population
The study was embedded within the Rotterdam Study, a prospective population-based 
cohort of persons aged 55 years or older in the municipality of Rotterdam, the Neth-
erlands. The rationale and design of the study have been described elsewhere 21. The 
baseline examination was completed between 1990 and 1993 (Rotterdam Study-I). In 
1999, the cohort was extended to include inhabitants who reached the age of 55 years 
after the baseline examination and persons aged 55 years or older who migrated into 
the research area (Rotterdam Study-II). Baseline participation for all RS cycles was 72% 
(14,926 of 20,744). The present study used data obtained from 6,498 participants at the 
third examination of the original cohort (Rotterdam Study-I) (1997-1999) and the fi rst ex-
amination of the extended cohort (Rotterdam Study-II) (2000-2001). After excluding 565 
participants with a history of CHD (defi ned as clinically manifest myocardial infarction, 
coronary artery bypass grafting, or percutaneous transluminal coronary angioplasty), 
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we had data from 5,933 asymptomatic participants. C-reactive protein (CRP) (n=3,029) 
and coronary artery calcium (CAC) score (n=3,678) measurements were available for 
a smaller group. The study was approved by the Medical Ethics Committee of Erasmus 
University, Rotterdam, the Netherlands, and all participants gave written informed con-
sent.
Risk Factors
We studied traditional cardiovascular risk factors, such as age, sex, body mass index, 
systolic blood pressure, treatment of hypertension, total and high-density lipoprotein 
cholesterol levels, use of lipid-lowering medication, smoking, and diabetes mellitus.
We also studied newer risk factors, such as levels of N-terminal fragment of prohor-
mone B-type natriuretic peptide (NT-proBNP), von Willebrand factor antigen levels, fi -
brinogen levels, chronic kidney disease (CKD) (estimated glomerular fi ltration rate <60 
mL/min per 1.73 m2), leukocyte count, CRP levels, homocysteine levels, uric acid lev-
els, CAC scores, carotid intima–media thickness (cIMT), peripheral arterial disease, and 
pulse wave velocity.
Clinical Outcomes
We obtained information on study outcomes from general practitioners and from letters 
and discharge reports from medical specialists. Events were classifi ed by study physi-
cians. Incident CHD was defi ned as a defi nite nonfatal or fatal myocardial infarction or 
death due to CHD. Defi nite and possible fatal CHD were coded by using the defi nitions 
applied within the Cardiovascular Health Study 22 and Atherosclerosis Risk in Com-
munities Study 23. Only fi rst CHD events were included in the analyses; 20 participants 
were lost to follow-up.
Statistical Analysis
We assessed the independent relationship of each marker to CHD incidence by using 
Cox proportional hazards models. We transformed markers with highly skewed distri-
butions to the natural logarithmic scale, and for CAC score we used the natural loga-
rithm of (CAC+1) to handle CAC scores of zero. To determine the functional form used 
for each marker, we examined restricted cubic spline transformations for continuous 
predictors 24 and used the likelihood ratio test to examine the linearity assumption. If 
appropriate, we chose the simplest form, usually a log-linear term. All models met the 
proportional hazards assumption as evaluated by the “cox.zph” function in R, version 
2.10.1 (R Foundation for Statistical Computing, Vienna, Austria). Multivariable-adjusted 
hazard ratios (HRs) were calculated for comparison of the highest versus the lowest 
quartile (as the reference) for each marker. 
Because median follow-up in the cohort was 6.8 years and most CHD risk prediction 
instruments, including the FRS, predict 10-year CHD risk, we used a parametric Weibull 
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proportional hazards regression model to estimate 10-year CHD risk from data available 
over a shorter follow-up period for each person. We fi rst fi t a Weibull prediction model 
to our data on the basis of the variables used in the FRS (age, sex, systolic blood pressure, 
treatment of hypertension, total and high-density lipoprotein cholesterol levels, current 
smoking, and diabetes mellitus) 1. We refer to this model as the “base model.” We then 
developed 12 new models, each containing the FRS variables with the addition of 1 
of the 12 newer risk markers (referred to as the “newer marker model”). The analyses 
including CAC score were additionally adjusted for the type of computed tomography 
scanner.
We compared the base model with the newer marker models by using the likelihood 
ratio chi-square test for global model fi t; using the difference in the optimism corrected 
c-statistic between each newer model and the base model, calculated by 100 bootstrap 
repetitions 24,25; and using the net reclassifi cation improvement (NRI) with the newer 
marker as suggested by Steyerberg and Pencina for survival data 26. The c-statistic is a 
measure of discrimination (the ability to distinguish between two persons, one with and 
one without a CHD event), and NRI specifi es the amount of correct reclassifi cation of 
estimated (not actual) events and nonevents to 10 years. The NRI estimates were based 
on the reclassifi cation tables classifying participants in 10-year CHD risk categories of 
low (<10%), intermediate (10%-20%), and high (>20%). We then repeated all of the 
analyses for men and women separately. 
Information on some markers and covariables was missing in up to 13% of partici-
pants. We performed multiple imputations of the missing values by using the Hmisc 
library of R (R-library: Hmisc, function: aregImpute). All analyses were performed with 
R, version 2.10.1. A 2-sided P value of less than 0.05 denoted statistical signifi cance.
RESULTS
Mean participant age was 69.1 years (SD, 8.5), and 59.4% were women. Table 1 reports 
the baseline values for traditional and newer risk markers. Demographic characteristics 
or risk factor values did not differ between the overall population and the subpopulation 
with CRP levels and CAC scores (data not shown). 
During a median follow-up of 6.8 years (25th, 75th percentiles: 5.8, 8.1 years), 347 
fi rst CHD events, including 190 nonfatal myocardial infarctions and 157 CHD deaths, 
occurred (Table 2).
Table 3 details HRs for incident CHD for traditional risk factors in the base model, as 
well as the performance measures for the base model (global model fi t and c-statistic).
Figure 1 illustrates adjusted HRs for comparisons of the highest versus lowest quartiles 
for each newer marker. Newer risk markers that were signifi cantly associated with inci-
dent CHD after adjustment for traditional risk factors were NT-proBNP levels (HR, 2.5 
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Table 1. Characteristics of the study population (N=5,933)
Variable Value *
Age (years) 69.1 (8.5)
Women (%) 3525 (59.4%)
Systolic blood pressure (mmHg) 143.3 (21.3)
Diastolic blood pressure (mmHg) 77.0 (11.2)
Antihypertensive treatment (N, %) 1392 (23.5%)
Body mass index (kg/m2) 27.0 (4.0)
Total cholesterol (mmol/L) 5.8 (1.0)
HDL cholesterol (mmol/L) 1.4 (0.4)
Triglyceride (mmol/L) 1.5 (0.8)
Lipid lowering medication (N, %) 605 (10.2%)
Glucose (mmol/L) 5.9 (1.5)
Diabetes mellitus (N, %) 767 (12.9%)
Current smoking (N, %) 1037 (17.5%)
Creatinine (umol/L) 76.0 [66.0, 87.0]
NT-proBNP (pmol/L) 9.5 [5.1, 18.1]
VWF (IU/mL) 1.2 [0.9, 1.6]
Fibrinogen:Ag (g/L) 3.8 [3.3, 4.4]
eGFR (mL/min/1.73 m2) 76.1 [67.0, 86.9]
CKD (N, %) 725 (12.2%)
Leukocyte count (*10^9/L) 6.8 (1.9)
CRP (mg/l) 2.3 [1.2, 4.4]
Homocysteine (umol/L) 13.5 [11.4, 16.6]
Uric acid (mmol/L) 0.3 [0.3, 0.4]
CAC 65.8 [4.4, 322.8]
IMT (mm) 1.0 [0.9, 1.1]
ABI 1.1 (0.2)
PAD (N, %) 830 (14.0%)
PWV (m/s) 12.6 [10.9, 14.8]
Abbreviations: HDL cholesterol, high density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-
type natriuretic peptide; VWF, von Willebrand factor; eGFR, estimated glomerular fi ltration rate; CKD, 
chronic kidney disease; CRP, C-reactive protein; CAC, coronary artery calcium ; IMT, carotid intima 
media thickness; ABI, ankle brachial index; PAD, peripheral artery disease; PWV, pulse wave velocity; 
NA, not applicable.
* Values are mean (SD) or numbers (percentages). Median [25th, 75th percentiles] is presented in case 
of skewed distribution.
[95% CI, 1.7-3.6]), fi brinogen levels (HR, 1.4 [CI, 1.1-2.0]), CKD (HR, 1.4 [CI, 1.1-1.8]), 
leukocyte count (HR, 1.8 [CI, 1.3-2.5]), CRP levels (HR, 1.6 [CI, 1.0-2.5]), homocysteine 
levels (HR, 1.4 [CI, 1.0-2.0]), CAC scores (HR, 6.2 [CI, 3.4-11.5]), cIMT (HR, 1.6 [CI, 
1.1-2.3]), and peripheral arterial disease (HR, 1.3 [CI, 1.0-1.7]).
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Table 4 details measures of improvement in model fi t, for the overall population and 
by sex, when each newer risk marker is added to the base model. In the overall popula-
tion, statistically signifi cant improvements were observed for NT-proBNP levels, fi brino-
gen levels, CKD, leukocyte count, CRP levels, homocysteine levels, CAC scores, cIMT, 
and peripheral arterial disease.
Table 5 summarizes the change in the c-statistic and the overall NRI when each newer 
risk marker is added to the base model. The maximum change in the c-statistic was 
observed for CAC score (0.05 [CI, 0.02-0.06]), followed by NT-proBNP level (0.02 [CI, 
0.01-0.04]). The highest overall net percentage of persons correctly reclassifi ed was 
also observed for CAC score (NRI, 19.3% [CI, 12.5%-26.2%]), with a smaller NRI for 
Table 2. Incidence of coronary heart disease in the total population 
Events Total events, n *
Events per 1000  
person-years, n *
Non-fatal MI 190 4.80
Fatal CHD 157 3.97
Defi nite fatal MI 30 0.76
Defi nite fatal CHD 88 2.22
Possible fatal CHD 39 0.99
Abbreviations: N, number; MI, myocardial infarction; CHD, coronary heart disease.
* Numbers, incident of coronary heart disease events; fatal and non-fatal, during a median follow-up 
time of 6.8 years in total population.
Table 3. Parameter estimates and performance measures of the “Framingham refi tted” model
Parameter
Framingham refi tted model
HR 95% CI
Age 1.08 1.06, 1.09
Male sex 1.95 1.55, 2.46
Systolic blood pressure 1.01 1.00, 1.01
Treatment for hypertension 1.21 0.95, 1.53
Total cholesterol 1.23 1.11, 1.37
HDL cholesterol 0.35 0.25, 0.49
Diabetes 1.35 1.03, 1.77
Current smoking 1.38 1.05, 1.82
Model performance measures
Model likelihood ratio Chi-square statistic 230.49
Model C-statistic * 0.73 0.71, 0.75
Abbreviations: HR, hazard ratio; CI, confi dence interval; HDL cholesterol, high density lipoprotein 
cholesterol.
* The C-statistic is corrected for over optimism using 100 bootstrap repetitions.
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Figure 1. Multivariable adjusted hazard ratio for incident CHD
Abbreviations: CHD, coronary heart disease; HR, hazard ratio; CI, confi dence interval; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; VWF, von Willebrand factor; CKD, chronic kidney disease; 
CRP, C-reactive protein; CAC, coronary artery calcium; IMT, carotid intima media thickness; PAD, 
peripheral artery disease; PWV, pulse wave velocity.
The fi gure shows multivariable adjusted Hazard ratios (95% confi dence interval) for incident coronary 
heart disease for the highest quartile of each marker (lowest quartile as reference). 
* CKD and PAD are modeled as categorical variables
Table 4. Global model fi t statistics for total population and by gender
Model
Likelihood ratio test statistics (X2)
Total population Men Women
FRS +NT-proBNP 58.7 * 35.6 * 25.7 *
FRS + VWF 2.2 2.3 0.1
FRS + Fibrinogen 7.2 * 11.4 * 0.1
FRS +CKD 5.4 * 7.8 * 0.3
FRS + Leukocyte count 14.1 * 19.8 * 0.8
FRS + CRP † 4.8 * NA NA 
FRS + Homocysteine 5.3 * 5.9 * 0.7
FRS + Uric acid 0.2 0.1 0.0
FRS + CAC 60.9 * 41.2 * 22.6 *
FRS + IMT 5.2 * 1.8 3.6
FRS + PAD 3.7 * 5.6 * 0.1
FRS + PWV 1.2 5.2 * 0.9
Abbreviations: X2, Chi-square statistic; FRS, Framingham risk score; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; VWF, von Willebrand factor; CKD, chronic kidney disease; CRP, C-reactive protein; 
CAC, coronary artery calcium; IMT, carotid intima media thickness; PAD, peripheral artery disease; 
PWV, pulse wave velocity.
Likelihood ratio Chi-square indicates the increase in model fi t after extending the Framingham model 
(including conventional risk factors) with each new marker. 
* Signifi cant improvement in model fi t (P< 0.05), evaluated by likelihood ratio Chi-square.
† For CRP, the power was not enough to perform the gender-specifi c analyses.
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Table 5. Discriminative ability of risk markers 
Marker
Change in c-statistic
(95% CI) 
NRI (95% CI) *
for Total Population
NT-proBNP 0.02 (0.01, 0.04) 7.6 (2.8, 12.5)
VWF 0.00 (0.00, 0.00) 0.4 (-1.7, 2.5)
Fibrinogen 0.00 (0.00, 0.01) 2.9 (-0.2, 6.0)
CKD 0.00 (0.00, 0.00) 2.7 (-0.2, 5.7)
Leukocyte count 0.01 (0.00, 0.02) 1.5 (-1.5, 4.6)
CRP † 0.00 (-0.01, 0.00) 2.0 (-2.3, 6.4)
Homocysteine 0.00 (0.00, 0.00) -0.3 (-3.0, 2.3)
Uric acid 0.00 (0.00, 0.00) 0.8 (-0.5, 2.1)
CAC † 0.05 (0.02, 0.06) 19.3 (12.5, 26.2)
IMT 0.00 (0.00, 0.00) 1.6 (-1.1, 4.4)
PAD 0.00 (0.00, 0.00) 0.6 (-1.8, 2.9)
PWV 0.00 (0.00, 0.00) 0.00 (-2.1, 2.1)
Abbreviations: NRI, net reclassifi cation improvement; CI, confi dence interval; FRS, Framingham risk 
score; NT-proBNP, N-terminal pro-B-type natriuretic peptide; VWF, von Willebrand factor; CKD, 
chronic kidney disease; CRP, C-reactive protein; CAC, coronary artery calcium; IMT, carotid intima 
media thickness; PAD, peripheral artery disease; PWV, pulse wave velocity.
* Percentage of net reclassifi cation improvement (95% CI) for the extended model versus the “Framing-
ham refi tted” model, using risk categories of <10%, 10%-20%, >20%. It is estimated as ([number of 
events reclassifi ed higher - number of events reclassifi ed lower] / number of events) + ([number of non-
events reclassifi ed lower - number of non-events reclassifi ed higher] / number of non-events).
† The analyses for CRP (n=3,029) and CAC score (n=3,678) were performed in a smaller group.
NT-proBNP (7.6% [CI, 2.8%-12.5%]). Changes in c-statistics and overall NRIs in total 
population were otherwise negligible or absent for every newer marker.
Table 6 summarizes the overall NRI when newer risk markers are added to the base 
model for the persons categorized at intermediate risk for a CHD event on the ba-
sis of the base model. In this subpopulation, NRI was highest for CAC score (39.3% 
[CI, 26.8%-51.7%]), followed by NT-proBNP level (33.0% [CI, 23.4%-2.6%]). All other 
markers resulted in NRIs of 10% or less in this subpopulation.
Table 7 details the intermediate NRI per gender; for men and women categorized at 
intermediate risk for a CHD event on the basis of the base model. With some excep-
tions, NRIs tended to be higher for men than for women, corresponding to the stronger 
associations (HRs) between the newer risk markers and CHD events in men.
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Table 6. Coronary heart disease risk reclassifi cation for the Framingham intermediate risk cat-
egory after extending the model with each marker
Extended Models
Events (%) Non-events (%)
NRI (95% CI) *
Up Down Up Down
FRS +NT-proBNP 29.0 16.4 9.8 30.2 33.0 (23.4, 42.6)
FRS + VWF 4.4 3.9 2.0 5.5 4.0 (-0.2, 8.1)
FRS + Fibrinogen 10.6 4.8 5.9 10.3 10.2 (4.5, 15.9)
FRS + CKD 10.0 3.2 5.4 8.4 9.8 (4.4, 15.1)
FRS + Leukocyte count 11.5 6.4 6.0 10.2 9.3 (3.2, 15.4)
FRS + CRP † 12.3 10.4 4.9 12.2 9.2 (0.2, 18.0)
FRS + Homocysteine 7.6 7.8 3.7 8.6 4.7 (-0.9, 10.3)
FRS + Uric acid 0.8 0.0 0.5 2.3 2.6 (1.0, 4.2)
FRS + CAC † 37.0 13.0 18.7 34.0 39.3 (26.8, 51.7)
FRS + IMT 6.0 4.2 4.3 7.1 4.6 (-0.05, 9.3)
FRS + PAD 6.8 2.1 4.2 6.8 7.3 (2.9, 11.7)
FRS + PWV 4.4 2.8 2.1 3.7 3.2 (-0.6, 7.1)
Abbreviations: NRI, net reclassifi cation improvement; CI, confi dence interval; FRS, Framingham risk 
score; NT-proBNP, N-terminal pro-B-type natriuretic peptide; VWF, von Willebrand factor; CKD, 
chronic kidney disease; CRP, C-reactive protein; CAC, coronary artery calcium; IMT, carotid intima 
media thickness; PAD, peripheral artery disease; PWV, pulse wave velocity.
* NRI is estimated as ([number of events reclassifi ed higher - number of events reclassifi ed lower] / 
number of events) + ([number of non-events reclassifi ed lower - number of non-events reclassifi ed 
higher] / number of non-events).
† The analyses for CRP (n=3,029) and CAC score (n=3,678) were performed in a smaller group.
Table 7. Coronary heart disease risk reclassifi cation for the Framingham intermediate risk cat-
egory, per gender
Extended Models
Intermediate NRI (95% CI) *
Men Women
FRS + NT-proBNP 36.3 (23.9, 48.8) 27.8 (12.8, 42.8)
FRS + VWF 6.8 (0.1, 13.4) 2.3 (-3.1, 7.8)
FRS + Fibrinogen 21.8 (12.3, 31.2) 1.4 (-2.6, 5.5)
FRS + CKD 10.1 (1.8, 18.4) 1.2 (-3.2, 5.6)
FRS + Leukocyte count 18.3 (7.9, 28.7) 1.6 (-3.7, 6.8)
FRS + Homocysteine 13.6 (5.5, 21.8) -1.8 (-7.0, 3.4)
FRS + Uric acid 2.5 (0.1, 4.9) -0.6 (-3.3, 2.1)
FRS + CAC 50.9 (33.7, 68.1) 25.2 (6.4, 44.0)
FRS + IMT 7.7 (1.4, 14.0) 13.7 (4.6, 22.9)
FRS + PAD 6.5 (-1.1, 14.1) -1.2 (-4.2, 1.7)
FRS + PWV 13.2 (6.2, 20.2) 3.8 (-0.8, 8.3)
NRI, net reclassifi cation improvement; CI, confi dence interval; FRS, Framingham risk score; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; VWF, von Willebrand factor; CKD, chronic kidney 
disease; CAC, coronary artery calcium; IMT, carotid intima media thickness; PAD, peripheral artery 
disease; PWV, pulse wave velocity.
* Percentage of net reclassifi cation improvement (95% CI) for the men/women at the intermediate risk 
category after extension of the “Framingham refi tted” model with each marker.
For CRP, the power was not enough to perform the gender-specifi c analyses.
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DISCUSSION
Among 12 newer CHD risk markers, CAC score provided the best improvement in CHD 
risk prediction and stratifi cation above the FRS, as measured by an increase in the c-sta-
tistic and clinically signifi cant reclassifi cation in the overall population and in persons 
categorized as intermediate risk by traditional cardiovascular risk factors. The fi nding is 
consistent with those of previous studies 3,4,27.
Improvements in CHD risk prediction with other newer risk markers, including cIMT, 
ankle–brachial index, and pulse wave velocity, which have been shown to be strong 
predictors of CHD in other studies 6,9,28-30, were modest. The better performance of CAC 
score compared with other vascular measures of atherosclerosis probably refl ects the 
disparity in contribution of various vascular beds in the disease process. However, be-
cause of variations across studies in the number of risk categories and thresholds and 
in clinical outcomes of interest, it is diffi cult to make direct comparisons of our fi ndings 
with those of other population studies.
A relatively new risk marker, NT-proBNP, has been shown to be a strong predictor 
of coronary events and death 11,13,31. Among serum biomarkers, NT-proBNP was most 
associated with CHD events and led to the greatest NRI both overall and among partici-
pants categorized as being at intermediate risk by traditional cardiovascular risk factors. 
Because elevation of various biomarker levels correlates with the various phases of the 
atherogenesis cascade 32, we speculate that the greater CHD risk prediction and reclas-
sifi cation with NT-proBNP compared with other serum biomarkers may correspond to 
its position in the later stages of the disease process. Specifi cally, an increase in BNP 
levels is viewed by some as a response to age-related, subclinical alterations in cardiac 
structure or function 33, so this biomarker may be more useful for CHD risk prediction 
at older ages. However, the 95% CIs for NRI with NT-proBNP overlap with those sur-
rounding NRIs from other markers, making it diffi cult to conclude that NT-proBNP is su-
perior to other markers. Nevertheless, our results suggest a potential role of NT-proBNP 
for inclusion in CHD risk prediction instruments.
Although other biomarkers, such as fi brinogen levels, CKD, leukocyte count, CRP 
levels, and homocysteine levels, were independently associated with the risk for later 
coronary events, their incremental value beyond traditional risk factors was marginal. 
Addition of these biomarkers to the base model yielded NRIs in the intermediate-risk 
group of 10% or less, with lower confi dence bounds below reclassifi cation thresholds 
that would probably be considered clinically useful.
Strengths of the current study include its large sample size, comparison of multiple 
markers that were all measured with standardized methods, use of hard end points to 
avoid misclassifi cation bias, and implementation of various statistical measures for as-
sessment of risk-scoring models. 
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There are also limitations. Our cohort comprised white participants aged 55 years or 
older; therefore, the generalizability of our fi ndings to younger and nonwhite popula-
tions remains uncertain. Also, due to the difference in the age range of our population 
compared with the Framingham population, we refi t a model on the basis of the Framing-
ham variables in our own population instead of using the original FRS algorithm. This 
implies that our results may differ from the settings that directly apply published versions 
of the FRS or its modifi cations. We fi t the Weibull model to estimate 10-year predicted 
risk for CHD from our actual median follow-up of 6.8 years. That extrapolation cannot 
be validated. Moreover, CAC score measurements in our study were performed with two 
types of scanners (electron beam and multidetector computed tomography). However, 
analyses using CAC score were adjusted for the type of scanner, and our results are 
similar to our previous fi ndings using the data from only our electron beam computed 
tomography cohort 27. Measurements of CRP levels and CAC score were available only 
in a subpopulation; however, general characteristics of that subpopulation did not ma-
terially differ from those of the larger population. Finally, we performed many statistical 
analyses to compare risk markers, and some of our statistically signifi cant fi ndings may 
have occurred by chance. However, our results show a consistent pattern for CAC score 
across statistical methods.
In summary, in this large population-based study, improvements in CHD risk pre-
diction and reclassifi cation with CAC score were statistically and clinically signifi cant. 
Increments in accuracy with other newer risk markers were less signifi cant. Further 
investigation is still needed to assess whether risk refi nements using CAC score lead to a 
meaningful change in clinical outcome. Moreover, whether to include any newer test in 
a risk prediction algorithm requires full consideration of the fi nancial and clinical costs 
of performing versus not performing the new test for both people and health systems. 
For CAC score in particular, exposing potentially healthy populations to radiation in a 
screening program requires careful considerations of the balance of risks and benefi ts.
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3.2.2 Framework for Evaluating Novel Risk Markers
Coronary heart disease (CHD) is characterized by the sudden onset of often catastrophic 
symptoms after decades of silent and insidious development. Identifying persons at risk 
for clinically evident CHD has become an important strategy for prevention, because 
treatment can reduce risk. The Framingham Heart Study, which began more than 60 
years ago, pioneered the identifi cation of clinical factors that were associated with fu-
ture coronary events 1. Data on these classic risk factors; age, sex, blood pressure, cho-
lesterol levels, diabetes, and smoking, can be combined using the Framingham risk 
score (FRS) to estimate a person’s chance of developing CHD over the next 10 years 2. 
The FRS has been extensively validated in many cohorts and countries 3, and it is an ac-
cepted tool in preventive medicine.
Although the FRS is simple and well-established, there is room for improvement. Most 
individuals with high scores do not develop disease in the next 10 years, and some 
with low scores nevertheless have heart attacks. Technological innovation and clinical 
research have provided new tools and insights that may increase the accuracy and dis-
crimination of cardiovascular risk prediction. Many putative risk markers have been de-
veloped, and although these markers are often associated with claims of “new” and “im-
proved” risk prediction 4, assessing their value has been diffi cult and controversial 5,6.
A FRAMEWORK FOR EVALUATION
There is a well-recognized framework for drug development, from basic science to ani-
mal models to studies in humans performed with increasing rigor and patient numbers 
(phases 1, 2, 3, and 4), with the ultimate goal of demonstrating improved clinical out-
comes at reasonable cost. Evaluation of diagnostic tests and risk markers has lagged 
behind that of drugs, in no small part because the regulatory requirements to market 
new tests are not as stringent as those for new drugs. The early phases of development 
of a novel risk marker (Table 1) are initial proof of principle, studies of predictive value 
in prospective studies, and comparison with established risk markers 6. A key hurdle is 
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to show that a new risk marker improves predictions over those made using standard 
clinical risk assessment. The proper statistical measure of improvement has been con-
troversial, with the main measures being the adjusted hazard ratio (or risk ratio or odds 
ratio); the c-index 7 (equal to the area under the receiver-operating characteristic curve); 
or new reclassifi cation measures (the net reclassifi cation improvement [NRI] index and 
the integrated discrimination improvement index) 8,9.
The c-index has been used as a metric of diagnostic test capability for more than 2 
decades 7 and basically assesses the discriminative power of a test (that is, the extent 
to which the probabilities assigned to patients who develop an event are higher than 
those assigned to patients who do not develop an event). Events that are inherently more 
unpredictable lead to a lower c-index than those that are more predictable. Although 
the c-index is a good measure of discrimination, it does not capture all of the aspects 
of a risk predictor 6. 
One important aspect of a risk marker is that it should be useful. An old truism about 
diagnostic tests was that if you would do the same thing regardless of the test result, then 
you should not order the test in the fi rst place. Applying this idea to a novel risk marker, 
if the test result could change the pretest levels of risk “enough” then the test could 
change clinical management. The key, of course, is to have agreed-upon standards for 
the risk levels that warrant changing therapy. In the case of CHD, current clinical guide-
lines suggest that persons with a 10-year risk of 20% or greater should be treated with 
drug therapy, such as statins, and those with a 10-year risk less than 10% are advised to 
follow a healthy lifestyle. Persons at intermediate risk (10% to 20%) should have indi-
vidualized assessment. Test results that move a person across a treatment threshold sug-
gest that the test could change clinical management. In particular, test results that move 
up the predicted risk for patients who develop events and move down the predicted 
Table 1. Phases of evaluation of a novel risk marker 
Proof of concept: Do novel marker levels differ between participants with and without out-
come?
Prospective validation: Does the novel marker predict development of future outcomes in a 
prospective cohort or nested case–cohort/case–cohort study?
Incremental value: Does the novel marker add predictive information to established, standard 
risk markers?
Clinical utility: Does the novel risk marker change predicted risk suffi ciently to change rec-
ommended therapy?
Clinical outcomes: Does the novel risk marker improve clinical outcomes, especially when 
tested in a randomized clinical trial?
Cost-effectiveness: Does use of the marker improve clinical outcomes suffi ciently to justify the 
additional costs of testing and treatment?
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risk for patients who do not (that is, move patients correctly across treatment thresholds) 
suggest that the test may be useful and have clinical value.
ROTTERDAM STUDY RESULTS
In this issue, the investigators of the Rotterdam Study report a study 10 that applied the 
framework for risk marker evaluation to assess 12 putative novel risk markers for CHD, 
including several that have generated considerable interest: N-terminal fragment of 
prohormone B-type natriuretic peptide (NT-proBNP) levels, C-reactive protein levels, 
carotid intima–media thickness, and coronary artery calcium (CAC) scores. The study 
design was strong because it compared all of these markers in a single group of patients 
and reported several measures of marker value, including adjusted hazard ratios, the 
c-index, and the NRI index. Regardless of the measure used, the CAC score added the 
most to the FRS, with NT-proBNP levels a close second. Both of these measures outdis-
tanced C-reactive protein and carotid intima–media thickness, risk markers that have 
been endorsed for assessing cardiovascular risk in particular patient groups 11. Perhaps 
more important than the rank-ordering of these markers was the observation that NT-
proBNP levels and CAC scores were the only markers of the 12 tested for which there 
was strong evidence of improvements in c-index and NRI index 10.
The results of these head-to-head comparisons among novel cardiac risk markers were 
interesting and informative, but they fall short of being defi nitive. First, the results should 
be replicated in other large cohorts, as the details of how the tests were done and the 
composition of the population may have affected the fi ndings. In particular, nearly every 
measure had a higher NRI index among men than among women, suggesting that test 
performance and its clinical value may depend on the characteristics of the population 
tested. The Rotterdam Study group had a mean age of 69.1 years, 59% were women, 
and presumably almost all participants had European ancestry.
Most important, it is not enough to show that a novel risk marker provides incremental 
statistical information (Table 1). The next phase in evaluation is to show that use of the 
novel risk marker has real clinical utility, by changing clinical management for the better 
and improving patient outcomes 6,12. The best way to do this is by randomly assigning 
participants to marker-guided evaluation or usual care to compare long-term outcomes 
and cost-effectiveness. A randomized trial of CAC screening has been proposed and 
would provide the best evidence for CAC measurement. This is an important issue be-
cause of possible unintended consequences of screening from radiation exposure and 
detection of incidental fi ndings on computed tomography. To my knowledge, no such 
study of NT-proBNP testing is being conducted, but the emerging evidence suggests that 
this marker is also worth further evaluation.
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Risk markers are increasingly important in management of patients with various dis-
eases. Before these markers are adopted into practice, we need strong evidence that 
they add meaningfully to simpler, standard clinical markers of risk. Statistically sig-
nifi cant evidence of independence is necessary, and requiring evidence that a marker 
reclassifi es risk is also becoming common. The ultimate standard for evaluation (Table 
1) is a demonstration that a new risk marker improves clinical outcomes at an affordable 
cost compared with current practice.
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3.4 Markers for Prediction of Cardiovascular Disease Risk
The article by Dr. Yeboah and colleagues compared the ability of several risk markers to 
improve prediction of coronary heart disease (CHD) and cardiovascular disease (CVD) 
among individuals at intermediate risk 1. The authors reported that coronary artery cal-
cium (CAC) provided superior reclassifi cation compared with other risk markers and 
recommended CAC as a tool for refi ning cardiovascular risk prediction in individuals at 
intermediate risk. While the added predictive ability of CAC in CHD risk prediction in 
the current study was substantial and confi rmed previous fi ndings 2, we believe that sup-
porting CAC as a candidate for CVD screening based on the results is less grounded. 
While it is straightforward to defi ne an intermediate-risk group for CHD, this is not the 
case for CVD because accepted thresholds are lacking. In the study by Yeboah et al, the 
authors included persons at intermediate CHD risk and therefore the results might not 
necessarily apply to persons at intermediate CVD risk 3. 
While CAC has shown to accurately predict CHD in different populations, CAC has 
not been proven to be a useful predictor for stroke 4. In the study by Yeboah et al 1, 
addition of CAC to the Framingham risk score provided overall net reclassifi cation im-
provement of 0.66 for CHD and of 0.47 for CVD risk prediction. The percent net cor-
rect reclassifi cation in the group without events hardly changed after adding a non-
CAC related outcome such as stroke (40.4% for CHD and 36.0% for CVD). However, 
the percent net correct reclassifi cation for those with events, which refl ects the ability 
to identify persons that will benefi t from intensive treatment, dropped from 25.5% for 
CHD to 10.6% for CVD.
The percent net correct reclassifi cation for persons with CHD events of 25.5% in the 
current study and 24.0% previously reported 2 imply that adding CAC to risk prediction 
models moves a substantial proportion of persons initially at intermediate risk to the 
high-risk group, where they qualify for more aggressive treatment. This supports the 
incorporation of CAC in CHD risk assessment. However, whether 10.6% net correct 
reclassifi cation of persons with CVD events provided by CAC is suffi ciently large to war-
rant recommending CAC as a screening tool for CVD is doubtful. 
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The general trend in developing new guidelines on cardiovascular risk prevention is 
moving towards focusing on broader CVD risk rather than on CHD risk only 5. However, 
before considering new markers for CVD risk prediction, all components of this broad 
outcome should be considered and limitations for stroke risk prediction recognized. 
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CHAPTER 4
Cardiovascular Risk Prediction in Women
CHAPTER 5
General Discussion

The concept of cardiovascular disease prevention is paired to the recognition that ath-
erosclerosis is a continuous process. Consequences of cardiovascular disease, once 
clinically evident, are immense for both patients and health care systems. In this regard, 
non-invasive measures for subclinical atherosclerosis are of particular interest to target 
medical prevention to those who need it, and thus limit under- or over-treatment of the 
disease.
In this thesis, the aim was to expand the knowledge on three measures of subclinical 
atherosclerosis burden; coronary artery calcifi cation, carotid intima-media thickness, 
and ankle-brachial index. The fi rst objective was to unravel the genetic determinants of 
these three measures using the powerful approach of genome-wide association (GWA) 
studies in the framework of the Cohorts for Heart and Aging Research in Genetic Epi-
demiology (CHARGE) Consortium 1. The next step was aimed at studying the ability of 
these three subclinical measures in cardiovascular risk prediction and comparing their 
predictive performances with those of several cardiovascular (bio)markers in predic-
tion of different cardiovascular outcomes. The fi nal objective was to study the recently 
modifi ed area of cardiovascular risk prediction in women. The cardiovascular predic-
tion studies were conducted within the framework of the Rotterdam Study, a population-
based cohort study among subjects aged 55 years and over 2.
In this chapter, the main fi ndings of this thesis are reviewed, methodological consid-
erations are addressed, and potential clinical implications of the fi ndings together with 
directions for future research are discussed. 
MAIN FINDINGS
Genetics of Subclinical Measures of Atherosclerosis
The second chapter of this thesis reports the results of the meta-analyses of GWA studies 
on three subclinical measures of atherosclerosis burden; coronary artery calcifi cation 
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(chapter 2.1), carotid intima-media thickness (chapter 2.2), and ankle-brachial index 
(chapter 2.3). 
We identifi ed several novel loci for coronary artery calcifi cation in a GWA meta-anal-
ysis of 9,961 subjects from 5 independent community-based cohorts with replication 
in 3 additional independent cohorts. We showed that multiple genetic loci are associ-
ated with development of both underlying coronary atherosclerosis and clinical events. 
Genome-wide signifi cant associations with coronary calcifi cation for single-nucleotide 
polymorphisms (SNPs) on 9p21 (near CDKN2A and CDKN2B), and on 6p24 (within the 
PHACTR1 gene), replicated for coronary artery calcifi cation and for association with 
myocardial infarction. We additionally found evidence for concordance of SNP associa-
tions with both coronary calcifi cation and myocardial infarction at a number of other 
loci, including 3q22 (MRAS gene), 13q34 (COL4A1/COL4A2 genes), and 1p13 (SORT1 
gene). The strength and consistency of SNP associations with coronary calcifi cation and 
with myocardial infarction suggest that the common mechanism of some genetic loci 
underlying myocardial infarction is development of early, underlying coronary athero-
sclerosis. 
Our meta-analysis of GWA data from 9 community-based studies, in over 40,000 par-
ticipants of European ancestry, revealed 3 new loci for common carotid intima-media 
thickness. We found genome-wide signifi cant associations for SNPs on chromosome 
8q24 (near ZHX2 gene), on 19q13 (2.3 kb from APOC1, a region that also includes 
APOE, APOC2, and APOC4), and on 8q23.1 (within the PINX1 gene). We also identi-
fi ed a suggestive locus on 6p22 (near SLC17A4 gene). In the meta-analysis of GWA data 
from 7 studies of carotid plaque, we identifi ed genome-wide signifi cant associations 
between 2 regions and the presence of carotid plaque. The most signifi cant signals were 
observed for 7q22 (near PIK3CG gene), and 4q31 (near EDNRA gene). Furthermore, 
two loci showed suggestive evidence for association with carotid plaque; 3p13 locus, 
and 19p13 (near LDLR gene). The identifi ed loci in GWA meta-analyses of carotid inti-
ma-media thickness or carotid plaque implicate LDL metabolism (APOC1), endothelial 
dysfunction (EDNRA), platelet biology (PIK3CG), and telomere maintenance (PINX1). 
Two of our identifi ed loci were also associated with coronary artery disease in the re-
cent large meta-analysis by the CARDIoGRAM Consortium 3; a locus near LDLR and a 
locus near EDNRA. Two other loci also showed suggestive associations with coronary 
artery disease; a locus near APOC1 and a locus near LRIG1. Conversely, none of SNPs 
reported to be associated with coronary artery disease in the CARDIoGRAM consortium 
showed signifi cant associations in our discovery meta-analyses of carotid artery traits.
The GWA meta-analysis for ankle-brachial index was conducted in more than 40,000 
subjects of European ancestry from 21 population-based cohorts. We sought replication 
of the 6 strongest SNP associations in 5 population-based studies and 3 clinical samples. 
We identifi ed and replicated one genome-wide signifi cant association on 9p21 region 
(near CDKN2B). In our discovery sample, over 3,000 subjects had peripheral arterial 
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disease (defi ned as ankle-brachial index below 0.9). However, none of the SNP associa-
tions for peripheral arterial disease was genome-wide signifi cant. Although we observed 
minimal overlap in the top SNP associations for the two traits, the directions of effect 
were consistent across the two phenotypes for the most signifi cant ankle-brachial index 
SNPs (lower ankle-brachial index, increased odds of peripheral arterial disease). More-
over, two previously reported candidate genes for peripheral arterial disease; DAB21P, 
CYBA, and one SNP associated with coronary artery disease (LDLR gene) were associ-
ated with ankle-brachial index in our GWAs.
Subclinical Measures of Atherosclerosis and Cardiovascular Risk Prediction
The third chapter of this thesis focuses on the ability of subclinical measures of athero-
sclerosis in prediction of different cardiovascular outcomes. We compared the predic-
tive ability of these measures with that of several biomarkers and markers of cardiac 
function. 
In chapter 3.1, we examined the predictive performance of carotid intima-media 
thickness in prediction of coronary heart disease and stroke. We showed that the addi-
tional predictive value of common carotid intima-media thickness above the traditional 
risk factors is small. In men, common carotid intima-media thickness did not signifi -
cantly improve risk stratifi cation based on traditional risk factors. In women, common 
carotid intima-media thickness showed a modest ability to reclassify people to a more 
accurate cardiovascular risk category.
We then compared the added values of the three subclinical measures of atheroscle-
rosis in coronary heart disease risk prediction with those of some emerging biomarkers 
in chapter 3.2. Among 12 risk markers understudy, we showed that improvements in 
coronary heart disease risk prediction, above the traditional risk factors, were most sta-
tistically and clinically signifi cant with the addition of coronary artery calcium scores. 
Among the biomarkers, NT-proBNP was most associated with coronary heart disease 
events and led to the greatest improvements in risk prediction. 
In chapter 3.3, we addressed the differential ability of the three subclinical measures 
in prediction of various components of cardiovascular disease; coronary heart disease, 
heart failure, and stroke, and compared them with some other newer biomarkers and 
markers of cardiac function. We showed that coronary artery calcium score, carotid 
intima-media thickness, and NT-proBNP provide the best increment in cardiovascular 
disease risk prediction above the traditional risk factors. The substantial gain in cardio-
vascular disease risk prediction by coronary artery calcifi cation was not accompanied 
by similar contributions to heart failure or ischemic stroke risk predictions. While the 
added value of carotid intima-media thickness was small, NT-proBNP considerably im-
proved risk predictions for all outcomes. 
We elaborated on the differential ability of coronary artery calcifi cation in prediction 
of different components of a broad cardiovascular outcome in chapter 3.4. We argued 
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that while suggesting coronary artery calcium as a good candidate for screening the risk 
of cardiovascular disease, in its broader sense, its limitations in stroke risk prediction 
should be recognized.
Cardiovascular Disease Risk Prediction in Women 
In chapter 4.1, we applied the new guidelines for cardiovascular risk prediction in 
women 4 to the population-based Rotterdam Study. We showed that focus on the broad 
cardiovascular endpoint as an outcome, and not only coronary heart disease, indeed 
better refl ects the cardiovascular risk distribution among women. Use of the new cut 
point of 10%, for defi ning high risk category for 10-year cardiovascular risk prediction 
in women, classifi ed a large group of women earlier in the high-risk category, where 
they qualify for timely treatment. By cross-examining short-term and long-term cardio-
vascular risk predictions, we highlighted a group of women at low-intermediate (5%-
10%) short-term risk for cardiovascular disease among whom about 25% were at high 
risk for cardiovascular disease at longer-term. We also showed that women at low short-
term but high long-term risk for cardiovascular disease had higher carotid intima-media 
thickness, higher carotid plaque prevalence, and lower ankle-brachial index, compared 
to women at low short-term/low long-term risk.
METHODOLOGICAL CONSIDERATIONS 
Promise and Pitfalls of Genome-Wide Association Studies
The past fi ve years have witnessed many gene discoveries made through the design of 
GWA studies. These studies were aimed at detecting variants at genomic loci that are 
associated with complex traits in the population and, in particular, at detecting associa-
tions between common single-nucleotide polymorphisms (SNPs) and common diseases 
such as cardiovascular disease. Despite the promising aspects of this approach, it holds 
many caveats and challenges which warrant consideration. 
GWAs reveal common variants with small effect sizes. Based on a non-hypothesis driv-
en approach, GWA studies simultaneously assess hundreds of thousands of variants 
across the whole genome for genetic variations that may associate with certain traits or 
diseases. In doing so, however, there is a great potential for false-positive fi ndings be-
cause of the large number of tested genetic markers. To separate true signals from noise, 
it has become conventional to apply the strict Bonferroni corrected P value of 5×10−8 
as the genome-wide signifi cance level. However, the design of current GWA studies 
makes them suitable mainly for the discovery of common variants conferring low to 
moderate risks. Most GWA studies have analyzed SNPs with minor allele frequencies of 
more than 1%-5%. Rare variants, with frequencies lying somewhere between 0.1%–1% 
General Discussion • 163
are not being examined by current GWA methods. Complex traits, however, can be 
caused collectively by multiple rare variants with moderate to high effects. 
Sample size matters. The typically small effect sizes detected for common variants in 
GWA studies necessitate large sample sizes to reach the stringent signifi cance thresh-
olds 5. In the GWA studies included in this thesis, we tried to include all studies with 
complete genotype-phenotype data, available at the time of the meta-analyses, in the 
discovery phase. Our discovery panel for the meta-analyses of the three subclinical 
measures therefore comprised sample sets of substantial size to maximize power. No-
tably, our initial effort on GWAs for the ankle-brachial index comprised about 22,000 
participants of European ancestry in which no loci surpassed the strict Bonferroni cor-
rected P value of 5×10−8. After expanding our sample size to over 40,000 subjects, 
which formed the ankle-brachial index GWA study included in this thesis, one locus 
survived the strict Bonferroni P value correction. 
Replication of fi ndings. Replication of the GWA fi ndings in independent samples is 
viewed as the ultimate proof of association 6. We sought for replication of our fi ndings 
in other studies that got their genotype data later, than our discovery phase, or could 
genotype a number of SNPs. Replication is also viewed as the “gold” standard of verify-
ing marginal effects 6,7. We, therefore, chose a less stringent signifi cance level for taking 
“promising” SNPs forward for replication, in order not to miss the genuine associations 
that do not pass the stringent set of criteria but are nonetheless real. As joint analysis 
has proven effi cient and is recommended in two-stage GWA studies 8, we then meta-
analyzed the effect estimates from the discovery phase with those of the replication 
stage and provided combined meta-analyses results. 
Population differences. GWA studies may falsely identify the associated genes related to 
diseases due to variations of allele frequencies from populations of different ethnicity or 
geographic origin. It is, therefore, emphasized for GWA studies to assess and adequately 
adjust for population stratifi cation. Population stratifi cation is typically examined by 
checking the distribution of test statistics, generated from the thousands of association 
tests, and their deviation from the null distribution (expected under the null hypothesis 
of no SNP is associated with the disease) using quantile–quantile (QQ) plots 9. Strong 
deviation from the null may suggest signifi cant differences in population subgroups. 
The degree of infl ation of test statistics can also be calculated by comparing the median 
over all test statistics with the theoretical median of the distribution of the test statistics 
under the null hypothesis; the so called genomic control (GC) 10. If population stratifi -
cation is present, several effective statistical methods are considered to correct for it 11. 
The GWA studies in this thesis included subjects of European ancestry only. Moreover, 
each study searched for population stratifi cation using QQ plots and calculating the 
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GC. If necessary, population stratifi cation was dealt with, for example by the principle 
component analysis.
Trait heterogeneity. Accurate phenotyping, to reduce trait heterogeneity, is another re-
quirement for conducting a good GWA study. Trait heterogeneity, which exists when 
a trait has been defi ned with insuffi cient specifi city, is viewed as a confounding factor 
in traditional statistical genetics of complex human disease 12. With quantitative traits, 
imprecision in measurement of phenotypes is usually not thought to have large sys-
tematic effects on the location of signifi cant associations in GWA studies, although 
it might introduce some degrees of variability 13. In the GWA studies included in this 
thesis, we tried to defi ne the phenotypes in a precise and harmonized manner across 
the studies. However, perfect harmonization was not always possible, particularly in the 
GWA studies for ankle-brachial index and for carotid plaque. In the ankle-brachial in-
dex GWA meta-analysis, the blood pressure measurement protocol and ankle-brachial 
index calculation, although standardized within each study, was heterogeneous across 
different participating studies. In the GWA study of carotid plaque, the plaque defi nition 
included the presence of any plaque in carotid bed in most studies and stenosis greater 
than 25% in others. Therefore, the remaining heterogeneity in phenotype defi nitions or 
the variability in measurement techniques might have compromised our ability to detect 
small associations.
Cardiovascular Risk Prediction; Prospects and Limitations
Cardiovascular risk prediction serves as the basis for clinical decision making for initia-
tion and intensity of treatment, raising population awareness of the disease, commu-
nicating knowledge about the risk to individuals, and motivating adherence to recom-
mended lifestyle changes or therapy. In classical cardiovascular risk scoring algorithms, 
combination of various traditional risk factors generates a risk score which is then con-
verted into an absolute probability of developing a cardiovascular event within a certain 
time frame. Over the past few years, substantial effort has been devoted to examining 
the addition of newer risk markers to established risk scoring systems. In doing so, the 
best scenario is to compare the added predictive ability of multiple risk markers within 
the same cohort 14. As part of this thesis, we examined the additive value of subclinical 
measures of atherosclerosis in prediction of different cardiovascular outcomes and com-
pared them with those of some other (newer) risk markers. Below, I address some issues 
pertinent to the cardiovascular risk prediction studies included in this thesis. 
Need for updating an existing risk prediction model. To assess the incremental value 
of a new risk marker, several investigators add it to the model containing the published 
risk scores. Performance of a risk prediction model, when applied to new individuals, is 
poorer than its performance in the sample in which it was developed 15. As a result, the 
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observed value of the new risk marker is a combination of the lower predictive perfor-
mance of the existing risk score in the new population and the true (added) value of the 
new marker. One solution is to update the existing prediction model to the new popu-
lation to improve its performance and to prevent infl ation of the estimates by the new 
marker. We, therefore, refi tted the current risk scoring algorithms into our population to 
accurately address the incremental value of newer risk markers. Notably, when compar-
ing the results of different studies on the added value of a risk marker, one should give 
careful attention to the baseline model upon which the incremental value is examined. 
Statistical measures for assessing the incremental predictive value. Following the grow-
ing interest in utilizing newer markers for cardiovascular risk prediction, recent guide-
lines recommend several statistical measures for assessing the increment in cardiovas-
cular risk prediction offered by newer risk markers 16-19. Besides providing evidence for 
the strength of association of the new marker with the outcome, it is now recommended 
to quantify improvements in model fi t, discrimination, calibration, and reclassifi cation 
of the risk prediction equations after addition of the new marker 18,19. For the risk predic-
tion studies included in this thesis, we employed the new statistical measures to quantify 
the gain in cardiovascular risk prediction using the newer risk markers.
Addressing the clinical utility of a new risk marker. To evaluate the clinical value of a 
risk marker, it is important to consider if the marker changes predicted risk suffi ciently 
to change recommended therapy 16,17. One way to quantify such concept is to calculate 
the percentage of individuals that are correctly reclassifi ed into clinically meaningful 
higher or lower risk categories with the addition of a new predictor; i.e. net reclassifi ca-
tion improvement (NRI) 18,20. Correct reclassifi cations are shifts to a higher risk category 
for events and shifts to a lower risk category for non-events. Defi nition of these risk 
groups, however, is often arbitrary and differs across studies. Since NRI is affected by 
proximity of the individual risk estimates to the cut-points used to defi ne the risk cat-
egories, comparisons of NRIs across different studies should be performed cautiously. 
To circumvent this problem, continuous NRI, that does not require stratifi cation of the 
population into risk groups, was introduced 20. Continuous NRI takes into account all 
movements in predicted probabilities, regardless of the extent of the movement which is 
often far from clinical signifi cance. In general, NRI increases as a function of the number 
of categories, with continuous NRI serving as the limiting case 21. In our study, coronary 
artery calcium provided a category-based NRI of 19% (based on three risk strata) and 
a continuous NRI of 45% in coronary heart disease risk prediction. For NT-proBNP, the 
category-based NRI for coronary heart disease risk prediction was 8%, compared to the 
continuous NRI of 22%. In some circumstances, use of continuous NRI is not clinically 
meaningful, as it is the case in cardiovascular research where established cut-points 
corresponding to clinical treatment strata exist 22. For the cardiovascular risk prediction 
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studies included in this thesis, we therefore reported NRIs using the clinically relevant 
risk categories for each cardiovascular outcome. 
Focusing on the intermediate risk category; clinical NRI. The use of newer markers to 
augment traditional cardiovascular risk prediction has attracted most attention for the 
individuals who fall into the intermediate risk category. The interest for focus specifi -
cally on intermediate-risk individuals is based on the premise that high-risk individuals 
should automatically be targeted for treatment measures, whereas low-risk individu-
als do not need specifi c intervention 22. The recommendations for the intermediate-risk 
individuals therefore remain less straightforward. Focusing on this group, a “clinical” 
NRI has been suggested by restricting the NRI measure to the intermediate risk stratum. 
Recently, it has been argued that, due to the symmetric nature of the reclassifi cation 
table, restricting NRI to the intermediate risk group may provide biased estimates 23. An 
adjusted version of clinical NRI has been proposed to determine the net improvement 
in the intermediate risk group 23. Application of the proposed adjustment method to our 
clinical NRI estimates in coronary heart disease risk prediction, presented in Table 4 
of chapter 3.2., reduced the clinical NRI for coronary artery calcium scores from 39% 
to 23% and for NT-proBNP from 33% to 23%. The adjusted NRI estimates can still be 
considered useful in clinical perspectives. 
Along with moving subjects out of the intermediate risk category into the low and high 
risk categories, which is the desired function of adding new markers, some individuals 
move into the intermediate risk category. At present, the guidelines do not provide any 
clear strategy on how to treat these people. Particularly, the current evidence is not suf-
fi cient to withdraw treatment from high-risk individuals who move into the intermediate 
risk category as the result of the new test. Consequently, until ample evidence suggests 
otherwise, more subjects would be deemed as being at high risk and thus qualify for 
treatment interventions. 
Broadening the outcome in cardiovascular prediction. Recently, there has been an in-
creasing recognition to focus the cardiovascular prediction systems on a broader car-
diovascular outcome instead of targeting coronary heart disease only 24. Expanding this 
continuum to include other entities, such as stroke or heart failure, will (i) methodologi-
cally increase power in risk prediction and (ii) clinically promote communication with 
individuals. It is now generally appreciated that although coronary and cerebrovascular 
disease share common risk factors, the strength of the associations and the contribu-
tion of risk factors to each disease entity is different 25-27. It should not be discarded 
that the same rule applies to the newer risk markers, meaning that contribution of a 
risk marker to prediction of the broad cardiovascular outcome is an aggregation of its 
different contributions to different components of the broad outcome. Our example of 
coronary artery calcifi cation clearly highlights this point by showing that calcifi cation 
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of the coronary arteries, which so far provides the most substantial improvement in 
coronary heart disease risk prediction, is not a good prognostic marker for stroke. We 
elaborate on this issue in chapter 3.4 of this thesis and argue that while suggesting coro-
nary artery calcium as a good candidate for screening the risk of cardiovascular disease, 
in its broader sense, its limitations in stroke risk prediction should be recognized. It 
seems therefore necessary to require the investigators to separately report the prediction 
estimates for the individual outcomes, along with presenting the estimates for the com-
bined outcome. At last, when comparing the results on the utility of newer risk markers 
in cardiovascular risk prediction, one should carefully consider that the defi nition of the 
composite cardiovascular outcome differs vastly across the studies. 
Generalizability. The cardiovascular prediction studies included in this thesis were all 
performed within the framework of the Rotterdam Study, a population-based cohort of 
individuals 55 years and older 2. The predictive performance of traditional risk factors 
decreases with age. It might therefore be more likely to witness the added predictive val-
ue of newer risk markers at older ages. This also implies that the results of the prediction 
studies in this thesis might not automatically be generalized to younger populations.
CLINICAL IMPLICATIONS & DIRECTIONS FOR FUTURE RESEARCH 
From GWA Studies to Translation
GWA studies represent one forward step toward a more complete understanding of 
the genetic architecture of complex disorders. Unbiased by prior biological knowledge, 
these studies have substantially changed the landscape of genetic associations for many 
traits. GWA studies have created a large database of regions of the human genome 
involved in each disease, containing a range of genes with a variety of functions, each 
of which can then be investigated biologically. Identifi cation of the disease associated 
genes by GWA studies provides new insights into disease mechanisms and can repre-
sent excellent potential therapeutic targets.
In the GWA studies included in this thesis, we identifi ed several new loci associated 
with the three subclinical measures of atherosclerosis burden. Interestingly, several of 
the identifi ed loci were also associated with coronary artery disease. In line with the 
general view that atherosclerosis is a continuous process, these shared genetic associa-
tions suggest a common etiology for subclinical and clinically apparent cardiovascular 
disease. Therefore, investigations to understand mechanisms underlying the genetic as-
sociations with subclinical carotid, coronary, and peripheral atherosclerosis may ulti-
mately suggest new strategies for prediction, prevention, and treatment of cardiovascu-
lar disease. A number of loci showed pleiotropic effects with several other phenotypes. 
Although these fi ndings reveal that the complexity underlying the genomic basis of 
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human disease is much greater than was initially thought, this pleiotropism may be very 
helpful in understanding some mechanisms shared among different diseases. 
Genetic prediction of cardiovascular disease, yet no help for clinicians? Although the 
main relevance of GWA studies lies in the insights into disease biology, one of the early 
promises of the GWA approach was to provide more accurate models for risk prediction 
based on the individual genetic profi le. Genotype-based risk predictions are (i) fi xed 
from birth, thus allowing for early risk prevention, and (ii) less susceptible to biological 
variation over life, and were therefore hoped to provide more precise estimates of indi-
vidual risk 28. However, the predictive power of disease risk ascertained from GWA data 
remains poor because for most diseases only a small proportion of genetic variance has 
been accounted for. Therefore, the results of the current genetic studies in cardiovascu-
lar risk prediction lie far below the level that can be considered clinically signifi cant. 
Sequencing based approaches are considered by some to turn up variants with stronger 
effects than GWA studies and to provide more meaningful risk prediction 29. However, 
the remaining limitation is the lower population frequency of the variants identifi ed 
through sequencing which makes the risk predictions benefi cial to the small number of 
individuals carrying each specifi c variant. Moreover, to seek such rare variants, studies 
with much larger sample size are required. 
Family history as an alternative? Instead of direct approaches to assess genetic risk, an 
important alternative is the use of family history in risk prediction. In our study, the ef-
fect estimate provided by family history in cardiovascular risk prediction (hazard ratio 
of 1.30, Table 2, chapter 3.3), was larger than those generally observed in GWA studies. 
As individual genetic variants or risk scores have not yet led to signifi cant improvements 
in risk prediction 30, family history is viewed as a simple, cheap, and clinically useful 
risk factor for cardiovascular disease, which likely represents the net effect of hundreds 
of genetic risk variants yet to be discovered. However, in our study, the added value of 
family history in assessment of cardiovascular risk above the traditional risk factors was 
marginal.
Next step, searching for pleiotropy across vascular beds. Subclinical measures of ath-
erosclerosis share common risk factors and are all predictive of future cardiovascular 
events. However, there is a low correlation across these measures in various major vas-
cular beds 31. The incomplete correlation among these vascular measures can rise from 
both genetic and environmental factors. Following successful completion of our GWA 
studies for the three subclinical measures, it is time to consider all three measures in 
one framework. We aim to unravel the common genetic variants shared across the three 
vascular measures and examine the extent to which the distribution of these traits can 
be attributed to pleiotropic effects of the same genetic variants.
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Moving forward with genetic and environmental interaction studies. Although athero-
sclerosis is viewed as a diffuse process, the degree of atherosclerosis varies from one 
arterial bed to another. This variation is likely to be the result of different risk factors, 
both genetic and environmental, as well as their interactions. We, therefore, will move 
forward with the GWA studies of the three subclinical measures implementing gene-
gene or gene-environment interactions. As a fi rst step and to secure the statistical power 
required for interaction studies 32, we plan to increase the sample sizes for the subclini-
cal measure GWA studies and include all studies that obtained their genotype data later 
than our initial GWA efforts for these traits and were therefore not included in the GWA 
studies described in this thesis.
Post-GWA era. The technology for identifying genetic differences is racing forward. 
It is now believed that making serious progress in understanding disease risk lies in 
developing a deeper “biological awareness” into genomic approaches to the study of 
complex disorders. Accordingly, new efforts are underway to accurately characterize 
low frequency and rare genetic variants inaccessible through GWA studies. Imputation 
using 1000 genome project 33 and high-throughput approaches such as next generation 
sequencing are examples of such efforts, that have been initiated within the framework 
of the CHARGE consortium 1, which results are being eagerly awaited. 
Cardiovascular Risk Prediction; Current Status and Future Directions 
Subclinical measures of atherosclerosis in cardiovascular risk prediction. Among the 
three measures of subclinical atherosclerosis burden studied in this thesis, coronary 
artery calcifi cation provides the best increment in coronary heart disease risk predic-
tion. The substantial gain in risk prediction provided by coronary artery calcium score 
above the traditional cardiovascular risk factors suggests use of this risk marker as a 
supplemental tool for refi ning coronary heart disease risk prediction, specially among 
subjects at intermediate risk. Our results, however, do not indicate the use of coronary 
calcium score in improving risk predictions for heart failure or stroke. Moreover, our 
fi ndings regarding the small added value of common carotid intima-media thickness in 
cardiovascular risk prediction do not support the routine use of this subclinical measure 
in cardiovascular screening programs above the traditional risk factors. Likewise, two 
recent large meta-analyses have shown that the improvement in cardiovascular risk 
prediction by either a single measurement of common carotid intima-media thickness 34 
or by quantifying the change in the thickness of common carotid artery over time 35 is 
unlikely to be of clinical importance. Recent evidence suggests that maximum intima-
media thickness of (and presence of plaque in) the internal carotid artery might be a 
better predictor for cardiovascular events 36. However, maximum thickness of the inter-
nal carotid artery also offers modest incremental value over the traditional risk scoring 
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algorithms in cardiovascular risk prediction. We also found a marginal added value for 
ankle-brachial index in cardiovascular risk prediction which falls below the level that 
could be considered clinically signifi cant. 
When we compared the ability of subclinical measures with several other emerging 
(bio)markers, another (relatively new) risk marker, NT-proBNP, provided a considerable 
improvement over the traditional risk factors in prediction of all cardiovascular out-
comes. NT-proBNP levels can therefore be considered as a reasonable supplemental 
tool for cardiovascular risk prediction in all settings. 
Search for ‘‘early markers’’ of cardiovascular disease. Risk markers may be informative 
either early or late in the atherosclerosis process, with some biomarkers refl ecting activ-
ity in biological pathways that precede the overt cardiovascular disease and other (bio)
markers triggered by the presence of ‘‘subclinical’’ cardiovascular disease. So far, grow-
ing evidence confi rms the incremental prognostic information provided by coronary ar-
tery calcium score and by NT-proBNP in cardiovascular risk prediction 37-41. The greater 
ability of these two markers in cardiovascular risk prediction might correspond to their 
position in the later stages of the disease process. Coronary artery calcium, in particular, 
is viewed as the vessel's memory of lifetime risk factor exposure 42. While identifying the 
disease at its ‘‘subclinical’’ stage is yet of profound value, the ideal situation would be to 
target the atherosclerosis process at its early stages. The pace of biomarker discoveries is 
accelerating, with the maturation of technologies such as proteomics and metabolomics. 
Such approaches may be particularly useful for identifying the cardiovascular disease 
biomarkers at early stages and in different pathways from those represented by existing 
biomarkers.
Need for large scale consortia in cardiovascular risk prediction. Following the success 
of large genetic consortia, large scale collaborative studies on the added value of emerg-
ing risk markers in cardiovascular risk prediction are underway 34,35. Methods for com-
bining discrimination and reclassifi cation estimates across studies are being developed. 
Given the lower cardiovascular incidence rates in women, such ‘‘mega-epidemiology’’ 
studies seem most relevant for this group. 
Focus on age-specifi c risk equations. In cardiovascular risk equations, age is in fact the 
single strongest risk factor for future cardiovascular events 43. Particularly, the inclusion 
of age in cardiovascular risk assessment can lead to under-representation of risk in 
younger individuals. One way to circumvent the central role of age in risk prediction is 
to derive age-specifi c risk equations for groups in narrow windows of age rather than 
developing models in populations with a wide age range in which age is included as a 
predictor variable. Without age in the cardiovascular risk equation and with a focus on 
General Discussion • 171
a specifi c age group, the role of other risk markers in cardiovascular risk prediction, and 
subsequently prevention, might become more prominent. 
Cardiovascular risk prediction, steps forward. (i) The more inclusive focus on total car-
diovascular outcome, and not targeting coronary heart disease only, together with (ii) 
extending the time frame in cardiovascular risk prediction, as a complement to short-
term (10-year) risk prediction, are two major steps forward towards improving the global 
cardiovascular risk assessment. Such approaches would help to avoid false reassurance 
for individuals who are at “low risk” for a coronary event at short-term but will become 
“high risk” for any cardiovascular event across the lifespan. In doing so, however, the 
importance and incidence of each particular cardiovascular outcome in the population 
of interest and the differential contribution of risk markers to various components of the 
more inclusive outcome should not be discarded. 
Phases of evaluation of a new risk marker. What is yet missing? Providing (statistically) 
signifi cant evidence of independence is a long-standing tradition in cardiovascular risk 
prediction. Recently, providing measures of model fi t, discrimination, and the evidence 
that a marker reclassifi es risk is also becoming common. The value of reclassifi cation for 
altering clinical management, however, remains largely theoretical because random-
ized trials specifi cally addressing this issue have not been performed. Therefore, the 
ultimate standard for evaluation remains to be a demonstration that a new risk marker 
improves clinical outcomes at an affordable cost compared with current practice. 
Among the measures of subclinical atherosclerosis burden, current evidence sug-
gests the use of coronary artery calcium in coronary heart disease screening programs. 
However, there is still need to design randomized control trials to assess the gain in 
Table 1. Phases of evaluation of a novel risk marker *
Proof of concept: Do novel marker levels differ between participants with and without out-
come?
Prospective validation: Does the novel marker predict development of future outcomes in a 
prospective cohort or nested case–cohort/case–cohort study?
Incremental value: Does the novel marker add predictive information to established, standard 
risk markers?
Clinical utility: Does the novel risk marker change predicted risk suffi ciently to change rec-
ommended therapy?
Clinical outcomes: Does the novel risk marker improve clinical outcomes, especially when 
tested in a randomized clinical trial?
Cost-effectiveness: Does use of the marker improve clinical outcomes suffi ciently to justify the 
additional costs of testing and treatment?
* Reproduced with permission (Hlatky MA. Ann Intern Med. 2012;156:468-469.)
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improvement in clinical outcomes before introducing the coronary calcium imaging 
into practice. Since refi ning risk estimation for the individuals at the low or high risk cat-
egories is not likely to alter the disease management, such trials should focus on the in-
dividuals at intermediate coronary heart disease risk in whom performing an additional 
test would assist in decision making. Moreover, the presumed benefi ts of the coronary 
calcifi cation screening still need to be weighed against its costs; both the direct fi nancial 
costs and the indirect costs such as exposing individuals to radiation or handling the in-
cidental fi ndings during the coronary calcium imaging. Finally, whether coronary artery 
calcium could be considered a good candidate for cardiovascular disease screening in 
its broader sense or should it only be focused on coronary heart disease remains to be 
investigated. 
Myth Revisited; Cardiovascular Disease not Just a Man’s Disease Anymore
Cardiovascular disease represents the leading cause of mortality for both men and wom-
en. In Europe, cardiovascular disease accounts for 43% of deaths in men and 55% in 
women. When different components of cardiovascular disease are considered, coronary 
heart disease represents 21% of deaths in men and 23% in women. Stroke comprises 
11% of deaths in men and 18% in women, whereas 11% of deaths in men and 15% in 
women are attributed to other cardiovascular events 44. Interestingly, breast cancer ac-
counts for 3% of all deaths. As life expectancy increases, and it does so particularly in 
women, the proportion of women with different components of cardiovascular disease 
shows an important rise. Of note, the decline in age adjusted cardiovascular mortality 
over the past 40 years has been of lesser magnitude in women compared to men. 
Appreciation of the impact of gender on cardiovascular risk assessment and manage-
ment has therefore been an area of increasing interest. The fi rst women-specifi c clinical 
recommendations for cardiovascular disease prevention, ‘‘A Guide to Preventive Car-
diology in Women’’, were published by the American Heart Association in 1999 45. In 
2005, the European Society of Cardiology initiated the ‘‘Women at Heart’’ program to 
coordinate research and educational initiatives on cardiovascular disease in women 44. 
Although gender disparities in recommendations for cardiovascular disease prevention, 
based on the misperceived lower risk in women, have started to decline, there is still a 
large room for improving cardiovascular risk prediction and prevention in women. 
Specifi c risk scoring algorithms for women. Women often share similar risk factors for 
cardiovascular disease with men. However, the magnitude of the effect of risk factors 
differs per gender. Some risk factors such as high blood triglyceride levels and low high-
density lipoprotein cholesterol play greater roles in increasing the risk of developing 
cardiovascular disease among women 46,47. Furthermore, diabetes and obesity appear to 
be stronger contributing risk factors for heart disease in women than men 48,49. Moreover, 
depression and other psychosocial risk factors, as well as autoimmune diseases have 
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been associated with a signifi cantly increased relative risk for cardiovascular disease in 
women and are considered as unrecognized risk factors 4. Additionally, some risk fac-
tors such as pregnancy complications [(pre)eclampsia 50 or gestational diabetes], poly-
cystic ovary syndrome 51, hormone therapy, and menopause are exclusive to women. 
It seems therefore reasonable to consider developing female-specifi c scoring systems 
including the risk factors that are more prevalent among women and/or the risk factors 
that make special contributions to cardiovascular risk in women. 
Extending the time horizon and outcome for risk prediction in women. Considering the 
risk factor burden in the context of longer time horizons, than 10 years, in assessing in-
dividuals’ risk for developing cardiovascular disease has recently gained interest. Given 
that cardiovascular risk is merely deferred by about 10 years in women, (i) extension of 
the time frame used for risk prediction seems particularly relevant in women, and (ii) it 
also seems reasonable to extend the risk assessment to older age groups in order to ac-
count for the delayed onset of cardiovascular disease in women. Moreover, there is an 
increasing recognition that risk models should focus on predicting global cardiovascular 
events and not targeting coronary heart disease only. Moving towards such a broader 
entity seems particularly true for women whose risks for stroke and heart failure through 
middle and older age typically exceed their risk for coronary heart disease 4. Such ap-
proaches will serve to identify more women at risk, overcoming some of the limitations 
of 10-year coronary heart disease risk prediction models.
Lowering risk thresholds for women. The most recent American Heart Association 
guideline for cardiovascular prevention in women recommends use of the lower cut-
point of 10% for all (fatal and non-fatal) cardiovascular events in defi ning the high risk 
category in women 4. European guidelines already estimate the risk of all cardiovascular 
events, although the focus is on the fatal cardiovascular events as opposed to a com-
bination of fatal and non-fatal events, and recommend use of the same risk thresholds 
for men and women 52. Use of this new cut-point, for all cardiovascular events, seems 
reasonable and identifi es a larger group of high-risk women, prior to the clinical presen-
tation of their disease, which qualify for (timely) treatment interventions. 
Need for more data in women. The majority of available data in women, which also 
serve as the basis for developing guidelines, is based on studies of coronary heart dis-
ease. Further studies are needed to focus on other specifi c outcomes of particular im-
portance in women, such as stroke and heart failure 4. In Europe particularly, there 
is a need to collect more epidemiological data on cardiovascular disease and its risk 
factors in women of different age groups in order to improve the accuracy of risk scor-
ing systems in women 44. The paucity of existing data calls for large scale collaborative 
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studies on cardiovascular risk prediction and on the added value of newer risk markers, 
particularly in women. 
New Concept; Cardiovascular Health 
A growing body of evidence indicates strong associations between risk factor levels 
across the lifespan and both cardiovascular and non-cardiovascular outcomes, as well 
as longevity. These observations have led to the development of a new concept; “car-
diovascular health” 53. The ideal “cardiovascular health” is defi ned by the absence of 
clinical cardiovascular disease and the simultaneous presence of favorable health be-
haviors (non-smoking, body mass index <25 kg/m2, physical activity at goal levels, and 
pursuit of a diet consistent with current guideline recommendations); together with the 
favorable health factors (untreated total cholesterol <200 mg/dL, untreated blood pres-
sure <120/<80 mm Hg, and fasting blood glucose <100 mg/dL) 53. The prevalence of 
ideal cardiovascular health has been reported to be low in several community-based 
study populations 54-56. The low prevalence estimates of cardiovascular health represent 
a starting point from which effectiveness of efforts to promote cardiovascular health and 
prevent cardiovascular disease can be monitored and compared 56.
Health is a broader construct than just the absence of clinically evident disease. Al-
though there appears to be substantial overlap between the components of “cardio-
vascular health” and “general health”, there are other components to “general health” 
related to physical, mental, and social functioning, among other factors, that have not 
been addressed in the concept of “cardiovascular health” 53. Future efforts should in-
clude consideration of the different important aspects of general health to arrive at a 
more comprehensive defi nition for “health” and consequently “healthy longevity”. 
A clearer identifi cation of the major determinants of “healthy longevity” would pro-
vide many possibilities for action throughout life with subsequent promotion in quality 
of life accompanied by improved long-term care for the elderly. Focusing on maintain-
ing optimal health can play a central role in overseeing the growing demand for long-
term care in ageing populations.
CONCLUDING REMARKS
In the GWA studies included in this thesis, we identifi ed several new loci associated 
with the three subclinical measures of atherosclerosis burden. Interestingly, several of 
the identifi ed loci were also associated with coronary artery disease, in line with the 
general view that atherosclerosis is a continuous process. Investigations to understand 
mechanisms underlying the genetic associations with subclinical carotid, coronary, and 
peripheral atherosclerosis may ultimately suggest new strategies for prediction, preven-
tion, and treatment of cardiovascular disease.
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Although the original concepts of risk prediction focused on coronary heart disease, 
the cardiovascular disease continuum has expanded to include other entities such as 
cerebrovascular disease and heart failure. The ultimate goal remains to be timely pre-
vention of the disease through state-of-the art knowledge on genetic and non-genetic 
risk markers. In the studies included in this thesis we found a marginal added value for 
both carotid intima-media thickness and ankle-brachial index in cardiovascular risk 
prediction which falls below the level that could be considered clinically important. 
We also showed that while coronary artery calcifi cation remains to be the best marker 
in coronary heart disease risk prediction, its use as a complementary tool for stroke or 
heart failure risk predictions has limitations. Therefore, whether coronary artery calcifi -
cation could be considered a good candidate for cardiovascular disease screening, in 
its broader sense, or should it only be focused on coronary heart disease remains to be 
investigated. 
The recent interest in (i) assessing individuals’ risk for developing various components 
of cardiovascular disease, and (ii) considering the risk factor burden in the context of 
longer time horizons, seems particularly relevant in women. Such approaches will serve 
to identify more women at risk, overcoming some of the limitations of 10-year coronary 
heart disease risk prediction models. Following the success of large genetic consortia, 
large scale collaborative studies in cardiovascular risk prediction and the added value 
of emerging risk markers, in particular in women, are warranted. 
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Atherosclerosis develops silently over decades before symptoms eventually occur, offer-
ing unique opportunities for timely detection and prevention. Although often detected 
when patients fi rst experience a major cardiovascular event, several techniques can be 
used to identify and quantify atherosclerosis when it is still at its subclinical stages. 
In this thesis, the aim was to expand the knowledge on three measures of subclinical 
atherosclerosis burden; coronary artery calcium, carotid intima-media thickness, and 
ankle brachial index. 
In chapter 2, we sought to unravel the genetic determinants of these three measures of 
subclinical atherosclerosis using the powerful approach of genome-wide association 
(GWA) studies in the framework of the Cohorts for Heart and Aging Research in Genetic 
Epidemiology (CHARGE) Consortium. 
We identifi ed several novel loci for coronary artery calcium in chapter 2.1. We showed 
that multiple genetic loci are associated with development of both underlying coronary 
atherosclerosis and clinical events. We found several signifi cant or suggestive genet-
ic loci; near CDKN2A and CDKN2B genes, within the PHACTR1 gene, MRAS gene, 
COL4A1/COL4A2 genes, and SORT1 gene in association with both coronary calcium 
and with myocardial infarction. These fi ndings suggest that the common mechanism of 
some genetic loci underlying myocardial infarction is development of early, underlying 
coronary atherosclerosis. 
Our meta-analysis of GWA data revealed 5 new loci for common cIMT and plaque, 
presented in chapter 2.2. These loci implicate LDL metabolism (APOC1), endothelial 
dysfunction (EDNRA), platelet biology (PIK3CG), and telomere maintenance (PINX1). 
Two of our identifi ed loci were also associated with coronary artery disease in the large 
meta-analysis by the CARDIoGRAM Consortium. Exploring the molecular, cellular and 
clinical consequences of genetic variation at these loci may yield novel insights into the 
pathophysiology of clinical and subclinical cardiovascular disease.
In the GWA meta-analysis for ankle brachial index, chapter 2.3, we identifi ed and 
replicated one genome-wide signifi cant association on 9p21 region (near CDKN2B). 
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However, none of the SNP associations for peripheral arterial disease was genome-wide 
signifi cant. Although we observed minimal overlap in the top SNP associations for the 
two traits, the directions of effect were consistent across the two phenotypes for the most 
signifi cant  ankle-brachial index SNPs. Moreover, two previously reported candidate 
genes for peripheral arterial disease; DAB21P, CYBA, and one SNP associated with coro-
nary artery disease (LDLR gene) were associated with  ankle-brachial index.
In chapter 3, our aim was to address the ability of the three subclinical measures in 
cardiovascular risk prediction and to compare their predictive performance with that of 
several cardiovascular (bio)markers in prediction of different cardiovascular outcomes. 
In chapter 3.1, we showed that the additional predictive value of common carotid 
intima-media thickness above the traditional risk factors in the prediction of coronary 
heart disease and stroke is small. While common carotid intima-media thickness did 
not signifi cantly improve risk stratifi cation based on traditional risk factors in men, it 
showed a modest ability to reclassify people to a more accurate cardiovascular risk 
category in women.
We compared the added value of the three subclinical measures of atherosclerosis 
in prediction of various components of cardiovascular disease; coronary heart disease, 
heart failure, and stroke with that of some emerging biomarkers in chapter 3.2 and 
chapter 3.3. We showed that coronary artery calcium and NT-proBNP provide the best 
increment in cardiovascular disease risk prediction above the traditional risk factors. In 
chapter 3.2, we showed that, among all markers under-study, improvements in coro-
nary heart disease risk prediction were most statistically and clinically signifi cant with 
the addition of coronary artery calcium scores, with NT-proBNP levels a close second. 
Although coronary calcium proved to be the best markers for coronary heart disease risk 
prediction, we showed in chapter 3.3 that the substantial gain in cardiovascular disease 
risk prediction by coronary artery calcium was not accompanied by similar contribu-
tions to heart failure or ischemic stroke risk predictions. In chapter 3.3 we also showed 
that NT-proBNP considerably improved risk predictions for all cardiovascular outcomes. 
These results imply that in the populations where heart failure or stroke are major con-
stituents of cardiovascular disease, use of coronary calcium as a complementary tool 
for risk prediction has limitations. NT-proBNP, however, can be considered as a reason-
able supplemental tool for cardiovascular risk prediction in all settings. However, mak-
ing a sensible decision on implementation of a new risk marker in cardiovascular risk 
prediction will ultimately necessitate reconsiderations of the cost, feasibility and safety 
of performing the new test. We elaborated on the differential ability of coronary artery 
calcium in prediction of different components of a broad cardiovascular outcome in 
chapter 3.4. We argued that while suggesting coronary artery calcium as a good candi-
date for screening the risk of cardiovascular disease, in its broader sense, its limitations 
in stroke risk prediction should be recognized.
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In chapter 4, we applied the new principles for cardiovascular risk prediction in women 
to the population-based Rotterdam Study. We showed that focus on the broad cardio-
vascular endpoint as an outcome and not only coronary heart disease indeed better 
refl ects the cardiovascular risk distribution among women. Use of the new cut-point 
of 10%, for defi ning high risk category for 10-year cardiovascular risk prediction in 
women, classifi ed a large group of women earlier in the high-risk category, where they 
qualify for timely treatment. By cross-examining short-term and long-term cardiovascu-
lar risk predictions, we highlighted a group of women at low-intermediate (5%-10%) 
short-term risk for cardiovascular disease among whom about 25% were at high risk for 
longer-term cardiovascular risk prediction. We also showed that women at low short-
term but high long-term risk for cardiovascular disease had higher carotid intima-media 
thickness, higher carotid plaque prevalence, and lower ankle-brachial index, compared 
to women at low short-term/low long-term risk.
In chapter 5, the main fi ndings of this thesis were reviewed, methodological consider-
ations were addressed, and potential clinical implications of the fi ndings together with 
directions for future research were discussed.
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Atherosclerose ontwikkelt zich ongemerkt gedurende een periode van tientallen jaren 
alvorens symptomen zich openbaren. Dit biedt unieke mogelijkheden voor vroegtijdige 
detectie en preventie. Hoewel atherosclerose vaak pas opgemerkt wordt wanneer pa-
tiënten zich voor het eerst presenteren met een ernstige cardiovasculaire aandoening, 
zijn er verschillende technieken om atherosclerose al in het subklinische stadium te 
identifi ceren en te kwantifi ceren. 
Het doel van het onderzoek gepresenteerd in dit proefschrift was om meer kennis te 
vergaren over drie maten van subklinische atherosclerose: coronaire calcium, intima-
mediadikte van de carotis en enkel-arm-index. 
In hoofdstuk 2 was ons doel de genetische determinanten van deze drie maten van 
subklinische atherosclerose te ontrafelen. Hiervoor hebben we de sterke techniek van 
genoomwijde associatiestudies (GWA) gebruikt binnen het Cohorts for Heart and Aging 
Research in Genetic Epidemiology (CHARGE) consortium. 
We hebben verschillende nieuwe loci voor coronaire calcium geïdentifi ceerd in 
hoofdstuk 2.1. We hebben laten zien dat meerdere genetische loci geassocieerd zijn met 
de ontwikkeling van zowel onderliggende coronaire atherosclerose als klinische eind-
punten. We hebben verschillende signifi cante of suggestieve genetische loci gevonden 
die geassocieerd waren met zowel de mate van coronaire calcium als met het optreden 
van een myocardinfarct; nabij de CDKN2A en CDKN2B genen, in het PHACTR1 gen, in 
het MRAS gen, in de COL4A1/COL4A2 genen en in het SORT1 gen. Deze bevindingen 
suggereren dat het mechanisme van sommige genetische loci voor het myocardinfarct 
ligt in ontwikkeling van vroege onderliggende coronaire atherosclerose. 
Onze meta-analyse van GWA data in hoofdstuk 2.2 onthulde 5 nieuwe loci voor 
intima-mediadikte en plaques in de carotis communis. Deze loci spelen een rol in 
het LDL-cholesterol metabolisme (APOC1), endotheeldysfunctie (EDNRA), biologie van 
bloedplaatjes (PIK3CG) en telomeerlengte (PINX1). Twee van de loci die we gevonden 
hebben waren ook geassocieerd met coronaire hartziekte in een grote meta-analyse 
van het CARDIoGRAM consortium. Het onderzoeken van de moleculaire, cellulaire en 
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klinische consequenties van genetische variatie binnen deze loci kan nieuwe inzichten 
geven in de pathofysiologie van (sub)klinische hart- en vaatziekten.
In de GWA meta-analyse van enkel-arm-index, hoofdstuk 2.3, hebben we één ge-
noomwijde signifi cante associatie in de 9p21 regio (nabij het CDKN2B gen) geïdenti-
fi ceerd en gerepliceerd, maar er waren geen genoomwijd signifi cante associaties met 
perifeer vaatlijden. Hoewel er slechts een minimale overlap was tussen de top SNPs 
voor beide uitkomsten, waren voor de meest signifi cante SNPs uit de enkel-arm-index 
analyse de richtingen van de effecten hetzelfde in beide fenotypes. Daarnaast waren 
twee eerder gerapporteerde kandidaatgenen voor perifeer vaatlijden (DAB21P en CYBA) 
en één SNP geassocieerd met coronaire hartziekte (LDLR gen) geassocieerd met de 
enkel-arm-index.
Het doel van hoofdstuk 3 was om te bestuderen hoe goed drie maten van subklinische 
atherosclerose verschillende manifestaties van hart- en vaatziekten kunnen voorspellen 
en om dit te vergelijken met enkele andere cardiovasculaire (bio)markers.
In hoofdstuk 3.1 hebben we laten zien dat de toegevoegde waarde van de intima-me-
diadikte van de carotis communis aan klassieke risicofactoren beperkt is als het gaat om 
het voorspellen van coronaire hartziekte en beroertes. Intima-mediadikte van de carotis 
communis gaf geen signifi cante verbetering in risicostratifi catie bij mannen, maar bleek 
wel de mogelijkheid te geven om vrouwen accurater in risicocategorieën voor hart- en 
vaatziekten te classifi ceren.
 We hebben de toegevoegde waarde van de drie subklinische maten van athero-
sclerose onderzocht voor het voorspellen van verschillende manifestaties van hart- en 
vaatziekten, namelijk coronaire hartziekte, hartfalen en beroertes. In hoofdstuk 3.2 en 
hoofdstuk 3.3 hebben we dit vergeleken we met enkele andere veelbelovende biomar-
kers. We hebben aangetoond dat coronaire calcium en NT-proBNP de grootste verbe-
teringen gaven in het voorspellen van hart- en vaatziekten na toevoeging aan klassieke 
risicofactoren. In hoofdstuk 3.2 hebben we laten zien dat van alle markers die we 
onderzocht hebben de toevoeging van coronaire calciumscores de risicovoorspellin-
gen voor coronaire hartziekte het meest statistisch en klinisch signifi cant verbeterde, 
op de voet gevolgd door NT-proBNP. Ondanks het feit dat coronaire calcium de beste 
toegevoegde marker was voor het voorspellen van coronaire hartziekten, hebben we 
in hoofdstuk 3.3 laten zien dat de substantiële verbetering in de voorspelling van hart-
ziekten door het toevoegen van informatie over coronaire calcium niet samenhing met 
vergelijkbare bijdragen aan het voorspellen van hartfalen of ischemische beroertes. In 
hoofdstuk 3.3 hebben we ook aangetoond dat NT-proBNP aanzienlijke verbeteringen 
gaf voor het voorspellen van alle onderzochte cardiovasculaire manifestaties. Deze re-
sultaten impliceren dat in bevolkingsgroepen waar hartfalen en beroertes veel voorko-
mende manifestaties van hart- en vaatziekten zijn, coronaire calcium beperkingen kent 
voor het voorspellen van het risico. NT-proBNP daarentegen kan gezien worden als een 
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redelijke aanvulling voor het voorspellen van hart- en vaatziekten in alle omstandighe-
den. Echter, om een verstandige keuze te maken voor de implementatie van een nieuwe 
risicomarker voor het voorspellen van hart- en vaatziekten zullen uiteindelijk ook over-
wegingen op het gebied van kosten, haalbaarheid en veiligheid van een nieuwe test 
in overweging genomen moeten worden. We hebben de differentiële capaciteit van 
coronaire calcium in het voorspellen van de verschillende manifestaties van hart- en 
vaatziekten verder benadrukt in hoofdstuk 3.4. We betoogden dat de beperkingen van 
coronaire calcium voor het voorspellen van beroertes onderkend moet worden bij het 
overwegen van coronaire calcium als kandidaat voor screening op het risico op hart- en 
vaatziekten in brede zin.
In hoofdstuk 4 hebben we de nieuwe aspecten van risicovoorspellingen voor hart- en 
vaatziekten toegepast op vrouwen uit het Erasmus Rotterdam Gezondheid Onderzoek 
(ERGO of ‘the Rotterdam Study’ - een prospectief cohort van de algemene bevolking 
van Rotterdam). We konden laten zien dat een brede defi nitie van cardiovasculaire aan-
doeningen als eindpunt, in tegenstelling tot enkel coronaire hartziekte, de cardiovascu-
laire risicoverdeling in vrouwen beter weergeeft. Met behulp van het nieuwe afkappunt 
van 10% om een hoog risico op hart- en vaatziekten binnen 10 jaar te defi niëren, werd 
een grote groep vrouwen eerder als hoog-risico bestempeld, waardoor zij in aanmer-
king komen voor tijdige behandeling. Door het tegen elkaar uitzetten van korte- en 
lange termijn voorspellingen van het risico op hart- en vaatziekten, konden we een 
groep vrouwen met een laag-intermediair korte termijn risico op hart- en vaatziekten 
(5%-10%) defi niëren, waarvan ongeveer 25% een hoog risico had op langere termijn. 
Ook hebben we laten zien dat, vergeleken met vrouwen met een laag risico op zowel 
korte- als lange termijn, vrouwen met een laag korte termijn risico maar een hoog lange 
termijn risico een grotere intima-mediadikte en een hogere prevalentie van plaques in 
de carotis hadden, en daarnaast ook een lagere enkel-arm-index.
In hoofdstuk 5 hebben we de belangrijkste bevindingen van dit proefschrift besproken, 
evenals de methodologische overwegingen, de potentiële klinische implicaties van de 
bevindingen en adviezen voor toekomstig onderzoek.
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1. PhD training
General academic skills 
The why and how of readable articles 2009 0.6
Research skills
MSc in Clinical Epidemiology 2006-2008
In-depth courses
Absolute Risk Prediction Workshop 2012 0.3
Next Generation Sequencing 2012 1.4
Markers and Prognostic Research 2010 0.7
Basic Course on R 2010 1.0
Workshop on Photoshop and Illustrator CS4 2010 0.3
Research Management Workshop 2010 1.0
Regression Analysis 2009 1.9
Survival Analysis 2009 1.9
Conceptual Foundation of Epidemiologic Study Design 2009 0.7
Writing Successful Grant Proposals 2009 0.3
Mendelian Randomization 2009 0.6
Genome-wide Association Analysis 2008 1.4
Workshop Browsing Genes and Genomes with Ensembl III 2008 0.6
Presentations at (inter)national conferences
American Heart Association Scientifi c Sessions, 
Los Angeles, California, USA
2012 1
Dutch Annual Epidemiology Conference (WEON), 
Rotterdam, the Netherlands
2012 1
Netherlands Consortium for Healthy Ageing (NCHA), 
Amersfoort, the Netherlands,
2012 1
American Heart Association Scientifi c Sessions, 
Orlando, Florida, USA
2011 1
Dutch Annual Epidemiology Conference (WEON), 
Ijmuiden, the Netherlands
2011 1
American Heart Association Cardiovascular Disease 
Epidemiology and Prevention Conference, Atlanta, Georgia, 
USA
2011 1
American Heart Association Scientifi c Sessions, 
Chicago, Illinois, USA
2010 1
Consortium meeting ‘CHARGE – Subclinical Atherosclerosis 
Working Group’. Houston, Texas, USA
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Consortium meeting ‘CHARGE – Subclinical Atherosclerosis 
Working Group’. Washington, D.C, USA
2009 0.5
Netherlands Consortium for Healthy Aging (NCHA), 
Delft, the Netherlands
2009 1
Consortium meeting ‘CHARGE – Subclinical Atherosclerosis 
Working Group’. Rotterdam, NL
2009 0.5
2. Teaching activities
Lecturing
Course organizer and lecturer, Women’s Health, NIHES 2012 2
Teaching assistant, Principles of Research in Medicine and 
Epidemiology, Erasmus Summer Program 
2008-2010 1
Teaching assistant, Study Design, NIHES 2009/2012 0.5
Supervising Master students
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PROPOSITIONS 
accompanying the thesis:  
“Subclinical Measures of Atherosclerosis; Genetics and Cardiovascular Risk Prediction”
1. The common mechanism of some genetic loci underlying myocardial infarction is 
development of early, underlying coronary atherosclerosis. (This thesis)
2. The added value of a risk marker in prediction of a broad cardiovascular outcome is an 
aggregation of its different contributions to various cardiovascular components. (This 
thesis)
3. Carotid intima-media thickness and ankle-brachial index both provide a marginal 
added value in cardiovascular risk prediction which falls below the level that could be 
considered clinically important. (This thesis)
4. Coronary artery calcifi cation is the best marker in coronary heart disease risk prediction. 
However, its use as a complementary tool for stroke or heart failure risk predictions has 
limitations. (This thesis)
5. Focusing on a broader cardiovascular outcome and considering the risk factor burden 
in the context of longer time horizons is particularly relevant for cardiovascular risk 
prediction in women. (This thesis) 
6. Superior doctors prevent the disease; mediocre doctors treat the disease before evi-
dent; inferior doctors treat the full blown disease. 
 (Huang Dee: Nai - Ching, 2600 B.C.)
7. Until a paradigm shift is adopted, cardiovascular biomarker research may remain fas-
cinating but probably unhelpful to medical practice and public health, if not also a 
potential major, unjustifi ed waste of effort and a sizeable threat to healthcare budgets. 
(John P.A. Ioannidis. Circulation Research. 2012;110:658-662)
8. Change your opinions, keep to your principles; change your leaves, keep intact your 
roots. (Victor Hugo)
9. The greatest challenge to any thinker is stating the problem in a way that will allow a 
solution. (Bertrand Russell)
10. An error does not become truth by reason of multiplied propagation, nor does truth 
become error because nobody sees it. (Mahatma Gandhi)
11. Cardiovascular risk prediction in women remains suboptimal. In this context, large 
scale collaborative studies for cardiovascular risk assessment and the added value of 
emerging risk markers are warranted.  
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Rotterdam, 8 October 2013
MKavousiStell.indd   1 24-8-2013   16:18:50
